Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Bio-Techne Corporation (TECH)
USD71.36
+0.06 (+0.08%)
US NASDAQ S&P 500
Healthcare Biotechnology
Address
614 McKinley Place N.E. 55413
Minneapolis, MN, US
Minneapolis, MN, US
CEO
Kim Kelderman
Website
bio-techne.com
IPO
1989-02-09
CIK 842023 ISIN US09073M1045
Description
Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research, diagnostics, and bioprocessing markets worldwide. The company operates through two segments, Protein Sciences, and Diagnostics and Spatial Biology. The Protein Sciences segment develops and manufactures biological reagents used in various aspects of life science research, diagnostics, and cell and gene therapy, such as cytokines and growth factors, antibodies, small molecules, tissue culture sera, and cell selection technologies. This segment also offers proteomic analytical tools for automated western blot and multiplexed ELISA workflow consists of manual and automated protein analysis instruments and immunoassays for use in quantifying proteins in various biological fluids. The Diagnostics and Genomics segment develops and manufactures diagnostic products, including controls, calibrators, and diagnostic assays for regulated diagnostics market, exosome-based molecular diagnostic assays, advanced tissue-based in-situ hybridization assays for spatial genomic and tissue biopsy analysis, and genetic and oncology kits for research and clinical applications; and sells products for genetic carrier screening, oncology diagnostics, molecular controls, and research, as well as instruments and process control products for hematology, blood chemistry and gases, and coagulation controls and reagents used in various diagnostic applications. The company was formerly known as Techne Corporation and changed its name to Bio-Techne Corporation in November 2014. Bio-Techne Corporation was incorporated in 1976 and is headquartered in Minneapolis, Minnesota.
News Sentiment (7d)
Based on only 1 article — low confidence
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Index membership
| Index | Added | Removed | Status |
|---|---|---|---|
| S&P 500 | 2021-08-27 | — | Active |
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
USD71.36
+0.06 (+0.08%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
4M
Beta
1.36
Float Shares
154.56M
Free Float %
98.8%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -1.94% | +0.47% | -14.62% | -20.36% | -22.77% | -19.37% | -12.02% | -41.67% | -53.61% | +87.43% | +43,253.45% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Analyst Consensus (25 ratings, all time)
Buy
Price Targets & DCF
Current price
71.36
Low
49.00
-31.3%
Consensus
61.33
-14.1%
Median
59.00
-17.3%
High
79.00
+10.7%
DCF (Unlevered)
22.57
-68.4%
DCF (Levered)
25.21
-64.7%
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
Ratings Trend (MoM)
71% Bullish
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 1 | 0 |
| Buy | 9 | 0 |
| Hold | 4 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Price Target Summary
| Period | # Analysts | Avg Target |
|---|---|---|
| Last Month | — | — |
| Last Quarter | — | — |
| Last Year | 8 |
69.63
-2.4%
|
| All Time | 19 |
84.04
+17.8%
|
Quality scores
Altman Z-Score
11.32
Safe zone
Piotroski F-Score
8 / 9
Strong
MOAT Score
6 / 10
Developing
Composite Rating
B
Overall Score
3 / 5
Medium
DCF Score
3 / 5
Medium
ROE Score
3 / 5
Medium
ROA Score
4 / 5
High
D/E Score
3 / 5
Medium
P/E Score
1 / 5
Low
P/Book Score
2 / 5
Medium
Operational MOAT
✗ Below peers
-
Revenue growth Biotechnology: +1.6%+5.2% ★ Q1'26: -1.5% (vs Q1'25)
-
EPS growth Biotechnology: +29.7%-56.2% Q1'26: +128.6% (vs Q1'25)
-
FCF margin FCF growth · Biotechnology: +16.2%+13.4% Q1'26: +24.9% (vs Q1'25)
-
EBIT margin Biotechnology: +0.0%+8.8% ★ Q1'26: +24.2% (vs Q1'25)
-
ROIC Biotechnology: -16.1%+3.6% ★ Q1'26: +10.0% (vs Q1'25)
-
Share dilution Biotechnology: -3.4%-0.7% ★ Q1'26: -1.3% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×2.05× Q1'26: 0.73× (vs Q1'25)
Valuation Multiples
From
To
Price Forecast (3Y)
From
To
Theoretical Return — If Invested Today
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Consensus Estimates
| Metric |
Jun 2011 actual |
Jun 2012 actual |
Jun 2013 actual |
Jun 2014 actual |
Jun 2015 actual |
Jun 2016 actual |
Jun 2017 actual |
Jun 2018 actual |
Jun 2019 actual |
Jun 2020 actual |
Jun 2021 actual |
Jun 2022 actual |
Jun 2023 actual |
Jun 2024 actual |
Jun 2025 actual |
Jun 2026 10 Rev. Ana. 8 EPS Ana. |
Jun 2027 9 Rev. Ana. 8 EPS Ana. |
Jun 2028 7 Rev. Ana. 3 EPS Ana. |
Jun 2029 3 Rev. Ana. 1 EPS Ana. |
Jun 2030 3 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
289.96M
est: 279.21M (+3.8%)
|
314.56M
est: 301.45M (+4.3%)
|
310.58M
est: 324.43M (-4.3%)
|
357.76M
est: 335.51M (+6.6%)
|
452.25M
est: 451.56M (+0.2%)
|
499.02M
est: 493.13M (+1.2%)
|
563.00M
est: 556.60M (+1.2%)
|
642.99M
est: 636.45M (+1.0%)
|
714.01M
est: 720.12M (-0.8%)
|
738.69M
est: 726.77M (+1.6%)
|
931.03M
est: 924.08M (+0.8%)
|
1.11B
est: 1.10B (+0.1%)
|
1.14B
est: 1.14B (-0.5%)
|
1.16B
est: 1.16B (+0.0%)
|
1.22B
est: 1.22B (+0.3%)
|
1.21B
1.20B – 1.22B
-0.7% YoY
|
1.26B
1.24B – 1.27B
+4.7% YoY
|
1.39B
1.38B – 1.39B
+9.7% YoY
|
1.45B
1.43B – 1.46B
+4.5% YoY
|
1.71B
1.69B – 1.73B
+17.8% YoY
|
| EBITDA |
173.68M
est: 168.67M (+3.0%)
|
174.66M
est: 173.69M (+0.6%)
|
172.98M
est: 177.89M (-2.8%)
|
180.57M
est: 178.60M (+1.1%)
|
192.93M
est: 191.13M (+0.9%)
|
191.99M
est: 187.16M (+2.6%)
|
179.36M
est: 166.49M (+7.7%)
|
200.60M
est: 176.09M (+13.9%)
|
211.89M
est: 198.72M (+6.6%)
|
378.41M
est: 342.10M (+10.6%)
|
249.87M
est: 226.20M (+10.5%)
|
413.76M
est: 300.37M (+37.8%)
|
457.11M
est: 349.17M (+30.9%)
|
313.14M
est: 345.97M (-9.5%)
|
216.88M
est: 363.18M (-40.3%)
|
360.58M
357.65M – 363.52M
-0.7% YoY
|
377.37M
371.57M – 380.28M
+4.7% YoY
|
414.07M
412.44M – 415.69M
+9.7% YoY
|
432.81M
427.83M – 437.29M
+4.5% YoY
|
509.77M
503.91M – 515.05M
+17.8% YoY
|
| EBIT |
160.76M
est: 159.99M (+0.5%)
|
164.08M
est: 162.20M (+1.2%)
|
160.66M
est: 167.99M (-4.4%)
|
161.39M
est: 161.11M (+0.2%)
|
155.71M
est: 152.89M (+1.8%)
|
149.23M
est: 145.15M (+2.8%)
|
119.32M
est: 120.07M (-0.6%)
|
136.14M
est: 119.85M (+13.6%)
|
133.72M
est: 137.50M (-2.7%)
|
295.67M
est: 158.89M (+86.1%)
|
162.13M
est: 139.49M (+16.2%)
|
312.70M
est: 238.87M (+30.9%)
|
349.87M
est: 278.55M (+25.6%)
|
201.43M
est: 237.85M (-15.3%)
|
106.97M
est: 249.69M (-57.2%)
|
247.90M
245.88M – 249.91M
-0.7% YoY
|
259.44M
255.45M – 261.44M
+4.7% YoY
|
284.67M
283.55M – 285.78M
+9.7% YoY
|
297.55M
294.13M – 300.63M
+4.5% YoY
|
350.47M
346.44M – 354.10M
+17.8% YoY
|
| Net Income |
112.30M
est: 113.89M (-1.4%)
|
112.33M
est: 110.20M (+1.9%)
|
112.56M
est: 113.87M (-1.1%)
|
110.95M
est: 115.63M (-4.0%)
|
107.74M
est: 114.95M (-6.3%)
|
104.48M
est: 99.66M (+4.8%)
|
77.29M
est: 74.76M (+3.4%)
|
125.35M
est: 108.37M (+15.7%)
|
96.07M
est: 91.59M (+4.9%)
|
229.30M
est: 198.54M (+15.5%)
|
140.41M
est: 128.87M (+9.0%)
|
272.05M
est: 196.47M (+38.5%)
|
285.26M
est: 246.63M (+15.7%)
|
168.11M
est: 284.40M (-40.9%)
|
73.40M
est: 301.66M (-75.7%)
|
307.90M
302.42M – 313.39M
+2.1% YoY
|
326.40M
308.74M – 344.07M
+6.0% YoY
|
377.07M
351.18M – 402.96M
+15.5% YoY
|
444.01M
437.38M – 449.99M
+17.8% YoY
|
503.11M
495.59M – 509.88M
+13.3% YoY
|
| SGA |
35.90M
est: 32.57M (+10.2%)
|
41.68M
est: 40.32M (+3.4%)
|
43.38M
est: 45.37M (-4.4%)
|
60.72M
est: 54.04M (+12.4%)
|
119.40M
est: 94.16M (+26.8%)
|
140.88M
est: 127.93M (+10.1%)
|
199.24M
est: 171.70M (+16.0%)
|
240.64M
est: 183.62M (+31.1%)
|
264.36M
est: 237.85M (+11.1%)
|
240.88M
est: 272.84M (-11.7%)
|
289.92M
est: 214.24M (+35.3%)
|
339.00M
est: 295.08M (+14.9%)
|
352.44M
est: 326.36M (+8.0%)
|
393.32M
est: 372.62M (+5.6%)
|
415.10M
est: 391.17M (+6.1%)
|
388.37M
385.21M – 391.52M
-0.7% YoY
|
406.45M
400.20M – 409.58M
+4.7% YoY
|
445.97M
444.22M – 447.72M
+9.7% YoY
|
466.16M
460.80M – 470.98M
+4.5% YoY
|
549.05M
542.74M – 554.74M
+17.8% YoY
|
| EPS |
0.76
est: 2.98 (-74.5%)
|
0.76
est: 3.14 (-75.8%)
|
0.76
est: 3.43 (-77.8%)
|
0.75
est: 3.38 (-77.8%)
|
0.73
est: 0.85 (-13.9%)
|
0.70
est: 0.90 (-22.6%)
|
0.52
est: 0.90 (-42.5%)
|
0.84
est: 1.11 (-24.3%)
|
0.64
est: 1.15 (-44.2%)
|
1.50
est: 1.07 (+39.6%)
|
0.91
est: 1.64 (-44.5%)
|
1.73
est: 1.98 (-12.6%)
|
1.81
est: 2.00 (-9.5%)
|
1.07
est: 1.78 (-39.9%)
|
0.47
est: 1.90 (-75.2%)
|
1.93
1.89 – 1.96
+1.8% YoY
|
2.08
1.93 – 2.15
+7.5% YoY
|
2.35
2.20 – 2.52
+13.3% YoY
|
2.78
2.74 – 2.82
+18.1% YoY
|
3.15
3.10 – 3.19
+13.3% YoY
|
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-06 | B | 3/5 | 3/5 | 3/5 | 4/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-05 | B- | 3/5 | 3/5 | 3/5 | 4/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-04 | B- | 3/5 | 3/5 | 3/5 | 4/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-01 | B- | 2/5 | 3/5 | 2/5 | 4/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-30 | B- | 2/5 | 3/5 | 2/5 | 4/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-29 | B- | 2/5 | 3/5 | 2/5 | 4/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-28 | B- | 2/5 | 3/5 | 2/5 | 4/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-27 | B- | 2/5 | 3/5 | 2/5 | 4/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-24 | B- | 2/5 | 3/5 | 2/5 | 4/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-23 | B- | 3/5 | 3/5 | 2/5 | 5/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-22 | B- | 3/5 | 3/5 | 2/5 | 5/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-21 | B- | 3/5 | 3/5 | 2/5 | 5/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-20 | B- | 3/5 | 3/5 | 2/5 | 5/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-17 | B- | 3/5 | 3/5 | 2/5 | 5/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-16 | B- | 3/5 | 3/5 | 2/5 | 5/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-15 | B- | 3/5 | 3/5 | 2/5 | 5/5 | 2/5 | 1/5 | 2/5 |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
270.17M
OE per share TTM
1.73
Owner's Yield
3.66%
Maintenance CapEx ratio
20.41%
Maint CapEx / Avg PPE
28.0%
Ownership Overview
Ownership breakdown
At a glance
Institutional holders
200
Total invested
520.33M
Insider transactions (90d)
3
Beneficial owners (>5%)
19
Beneficial owners (>5%)
| # | Reporting person | Amount owned | % of class | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Type | Citizenship | Filing date | SEC filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | (1) BlackRock, Inc. | 13.84M | 8.70% | — | — | 13.84M | — | HC | Delaware | 2024-10-21 | ↗ |
| 2 | 52-0556948 | 9.42M | 5.90% | 9.14M | — | 9.42M | — | IA | — | 2024-11-14 | ↗ |
| 3 | The Vanguard Group - 23-1945930 | 4.43M | 11.27% | — | 66.4K | 4.26M | 162.8K | IA | Pennsylvania | 2022-02-09 | ↗ |
| 4 | Eaton Vance Management 04-3101341 | 2.03M | 11.00% | — | — | 2.03M | — | IA | United States of America | 2018-02-14 | ↗ |
| 5 | Capital Management, LLC | 2.03M | 5.41% | 1.30M | — | 2.03M | — | IA | State of Maryland | 2018-02-14 | ↗ |
| 6 | Delaware Management Business Trust | 1.89M | 5.12% | 1.89M | — | 1.89M | — | IA | State of Delaware | 2014-02-14 | ↗ |
| 7 | Delaware Management Holdings Inc. | 1.89M | 5.12% | 1.89M | — | 1.89M | — | HC | State of Delaware | 2014-02-14 | ↗ |
| 8 | Macquarie Bank Limited | 1.89M | 5.12% | — | — | — | — | CO | State of Delaware | 2014-02-14 | ↗ |
| 9 | Macquarie Group Limited | 1.89M | 5.12% | — | — | — | — | HC | State of Delaware | 2014-02-14 | ↗ |
| 10 | Brown Capital Management, LLC | 1.70M | 4.51% | 1.06M | — | 1.70M | — | IA | State of Maryland | 2019-02-14 | ↗ |
| 11 | George S. Loening | 1.34M | 3.60% | — | 1.34M | — | — | HC, IN | Delaware | 2018-02-14 | ↗ |
| 12 | Select Equity Group, L.P. | 1.34M | 3.60% | — | 1.34M | — | — | IA | Delaware | 2018-02-14 | ↗ |
| 13 | 1,169,962 | 1.17M | 3.15% | 1.17M | — | 1.17M | — | IA | Sydney, New South Wales Australia | 2015-02-13 | ↗ |
| 14 | 1,169,962 deemed beneficially owned due to reporting person’s ownership of Delaware Management Busin | 1.17M | 3.15% | 1.17M | — | 1.17M | — | HC | Sydney, New South Wales Australia | 2015-02-13 | ↗ |
| 15 | Management Business Trust whose individual holdings are shown on the following forms. | 1.17M | 3.15% | — | — | — | — | HC | Sydney, New South Wales Australia | 2015-02-13 | ↗ |
| 16 | individual holdings are shown on the following forms | 1.17M | 3.15% | — | — | — | — | CO | Sydney, New South Wales Australia | 2015-02-13 | ↗ |
| 17 | Morgan Stanley | 995.7K | 2.70% | 988.3K | — | — | 13.00 | HC, CO | The state of organization is Delaware. | 2013-04-08 | ↗ |
| 18 | Morgan Stanley Investment Management Inc. | 995.7K | 2.70% | 988.3K | — | — | 13.00 | IA, CO | The state of organization is Delaware. | 2013-04-08 | ↗ |
| 19 | Bio-Techne Corporation | 150.0K | 7.20% | 150.0K | — | 150.0K | — | CO | Minnesota | 2019-04-15 | ↗ |
Institutional Activity (13F)
Institutional ownership trend
From
To
13F snapshot — 2026 Q1
Investors holding
200
-406 vs prev Q
New positions
18
Closed positions
400
Increased
79
Reduced
76
Put/Call ratio
0.00
Calls held
—
Puts held
—
Top institutional holders
| # | Investor | Shares / Δ | Mkt value / Δ | Own% / Δ | Weight% / Δ | Avg px / Perf. | Hold / Status |
|---|---|---|---|---|---|---|---|
| 1 | MACQUARIE MANAGEMENT HOLDINGS, INC. | 1.77M +1.8M (+100.0%) | 104.39B +104.4B (+100.0%) | 1.14% +1.139 pp | 0.16% +0.157 pp | USD58.81 +0.0% | 1 qtrs NEW |
| 2 | — | 379.4K +379.4K (+100.0%) | 22.31B +22.3B (+100.0%) | 0.24% +0.243 pp | 0.32% +0.321 pp | USD58.81 +0.0% | 1 qtrs NEW |
| 3 | VANGUARD GROUP INC | 17.81M -121.5K (-0.7%) | 1.05B +49.9M (+5.0%) | 11.43% +0.045 pp | 0.02% +0.000 pp | USD46.87 +25.5% | 45 qtrs — |
| 4 | BLACKROCK, INC. | 12.13M +242.0K (+2.0%) | 713.31M +52.0M (+7.9%) | 7.78% +0.237 pp | 0.01% +0.001 pp | USD79.40 -25.9% | 6 qtrs — |
| 5 | MORGAN STANLEY | 8.35M +1.1M (+15.3%) | 490.79M +88.2M (+21.9%) | 5.36% +0.760 pp | 0.03% +0.005 pp | USD70.81 -16.9% | 45 qtrs — |
| 6 | STATE STREET CORP | 5.81M +58.6K (+1.0%) | 341.81M +21.7M (+6.8%) | 3.73% +0.077 pp | 0.01% +0.000 pp | USD68.04 -13.6% | 46 qtrs — |
| 7 | WELLINGTON MANAGEMENT GROUP LLP | 5.73M +618.9K (+12.1%) | 337.22M +52.7M (+18.5%) | 3.68% +0.432 pp | 0.06% +0.009 pp | USD59.82 -1.7% | 45 qtrs — |
| 8 | GEODE CAPITAL MANAGEMENT, LLC | 4.93M +2.6K (+0.1%) | 289.50M +15.8M (+5.8%) | 3.16% +0.035 pp | 0.02% +0.000 pp | USD64.04 -8.2% | 45 qtrs — |
| 9 | PRICE T ROWE ASSOCIATES INC /MD/ | 4.08M +725.1K (+21.6%) | 239.66M +53.3M (+28.6%) | 2.62% +0.488 pp | 0.03% +0.006 pp | USD71.05 -17.2% | 45 qtrs — |
| 10 | MASSACHUSETTS FINANCIAL SERVICES CO /MA/ | 4.01M +2.5M (+164.4%) | 235.99M +151.6M (+179.6%) | 2.58% +1.615 pp | 0.08% +0.050 pp | USD62.73 -6.2% | 37 qtrs — |
| 11 | MAVERICK CAPITAL LTD | 3.85M +838.3K (+27.8%) | 226.47M +58.9M (+35.1%) | 2.47% +0.559 pp | 2.43% +0.191 pp | USD56.32 +4.4% | 4 qtrs — |
| 12 | INVESCO LTD. | 3.68M -267.4K (-6.8%) | 216.34M -3.2M (-1.4%) | 2.36% -0.145 pp | 0.03% -0.001 pp | USD65.88 -10.7% | 45 qtrs — |
| 13 | NEUBERGER BERMAN GROUP LLC | 3.13M -177.8K (-5.4%) | 184.04M +61.3K (+0.0%) | 2.01% -0.091 pp | 0.14% +0.003 pp | USD32.97 +78.4% | 45 qtrs — |
| 14 | SELECT EQUITY GROUP, L.P. | 2.84M +585.5K (+26.0%) | 166.85M +41.6M (+33.2%) | 1.82% +0.391 pp | 0.72% +0.203 pp | USD68.51 -14.2% | 16 qtrs — |
| 15 | AMERIPRISE FINANCIAL INC | 2.80M -16.7K (-0.6%) | 164.58M +8.0M (+5.1%) | 1.80% +0.009 pp | 0.04% +0.001 pp | USD68.33 -13.9% | 45 qtrs — |
| 16 | MAIRS & POWER INC | 2.77M -39.9K (-1.4%) | 162.76M +6.6M (+4.2%) | 1.78% -0.006 pp | 1.57% +0.099 pp | USD33.98 +73.1% | 46 qtrs — |
| 17 | DF DENT & CO INC | 2.59M -188.7K (-6.8%) | 152.45M -2.3M (-1.5%) | 1.66% -0.102 pp | 2.19% +0.196 pp | USD49.30 +19.3% | 46 qtrs — |
| 18 | MACKENZIE FINANCIAL CORP | 2.41M -145.4K (-5.7%) | 142.44M +54.7K (+0.0%) | 1.55% -0.076 pp | 0.17% -0.004 pp | USD88.58 -33.6% | 19 qtrs — |
| 19 | WILLIAM BLAIR INVESTMENT MANAGEMENT, LLC | 2.40M +688.6K (+40.3%) | 141.04M +45.9M (+48.3%) | 1.54% +0.454 pp | 0.39% +0.148 pp | USD67.08 -12.3% | 11 qtrs — |
| 20 | SUMITOMO MITSUI TRUST HOLDINGS, INC. | 2.37M +12.5K (+0.5%) | 139.27M +8.2M (+6.3%) | 1.52% +0.026 pp | 0.08% +0.006 pp | USD74.57 -21.1% | 25 qtrs — |
| 21 | ALLIANCEBERNSTEIN L.P. | 2.36M +1.4M (+157.8%) | 139.08M +88.0M (+172.5%) | 1.52% +0.935 pp | 0.04% +0.028 pp | USD57.16 +2.9% | 45 qtrs — |
| 22 | UBS GROUP AG | 2.22M +714.8K (+47.4%) | 130.81M +46.8M (+55.8%) | 1.43% +0.469 pp | 0.02% +0.008 pp | USD60.50 -2.8% | 45 qtrs — |
| 23 | RGM CAPITAL, LLC | 2.15M -148.0K (-6.4%) | 126.56M -1.4M (-1.1%) | 1.38% -0.079 pp | 6.14% +0.758 pp | USD54.79 +7.3% | 4 qtrs — |
| 24 | DURABLE CAPITAL PARTNERS LP | 2.09M +692.9K (+49.6%) | 122.85M +45.2M (+58.2%) | 1.34% +0.454 pp | 1.16% +0.587 pp | USD56.68 +3.8% | 2 qtrs — |
| 25 | AMERICAN CENTURY COMPANIES INC | 1.93M -109.3K (-5.4%) | 113.41M +51.1K (+0.0%) | 1.24% -0.056 pp | 0.06% -0.001 pp | USD61.40 -4.2% | 45 qtrs — |
| 26 | SNYDER CAPITAL MANAGEMENT L P | 1.93M +207.7K (+12.1%) | 113.32M +17.7M (+18.5%) | 1.24% +0.145 pp | 2.11% +0.304 pp | USD66.76 -11.9% | 46 qtrs — |
| 27 | DIMENSIONAL FUND ADVISORS LP | 1.79M +83.8K (+4.9%) | 105.52M +10.4M (+10.9%) | 1.15% +0.066 pp | 0.02% +0.002 pp | USD53.24 +10.5% | 45 qtrs — |
| 28 | BANK OF NEW YORK MELLON CORP | 1.79M -139.4K (-7.2%) | 105.31M -2.1M (-1.9%) | 1.15% -0.076 pp | 0.02% -0.002 pp | USD59.91 -1.8% | 45 qtrs — |
| 29 | GOLDMAN SACHS GROUP INC | 1.69M +156.7K (+10.2%) | 99.56M +14.1M (+16.5%) | 1.09% +0.111 pp | 0.01% +0.002 pp | USD63.00 -6.7% | 45 qtrs — |
| 30 | NORGES BANK | 1.69M +1.7M (+100.0%) | 99.49M +99.5M (+100.0%) | 1.09% +1.086 pp | 0.01% +0.011 pp | USD58.81 +0.0% | 1 qtrs NEW |
| 31 | CAPITAL RESEARCH GLOBAL INVESTORS | 1.62M -6.6K (-0.4%) | 95.21M +4.8M (+5.3%) | 1.04% +0.007 pp | 0.02% +0.001 pp | USD53.04 +10.9% | 3 qtrs — |
| 32 | CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 1.56M -20.5K (-1.3%) | 91.69M +3.8M (+4.3%) | 1.00% -0.002 pp | 0.01% +0.000 pp | USD62.82 -6.4% | 45 qtrs — |
| 33 | BROWN ADVISORY INC | 1.54M -321.1K (-17.2%) | 90.83M -12.9M (-12.5%) | 0.99% -0.193 pp | 0.13% -0.008 pp | USD69.66 -15.6% | 11 qtrs — |
| 34 | RUANE, CUNNIFF & GOLDFARB L.P. | 1.47M -7.8K (-0.5%) | 86.21M +4.2M (+5.2%) | 0.94% +0.005 pp | 1.35% -0.012 pp | USD55.20 +6.5% | 3 qtrs — |
| 35 | CHAMPLAIN INVESTMENT PARTNERS, LLC | 1.40M -298.5K (-17.5%) | 82.56M -12.1M (-12.8%) | 0.90% -0.180 pp | 0.84% +0.122 pp | USD61.58 -4.5% | 31 qtrs — |
| 36 | NORTHERN TRUST CORP | 1.33M -89.5K (-6.3%) | 78.35M -743.2K (-0.9%) | 0.85% -0.048 pp | 0.01% 0.000 pp | USD51.49 +14.2% | 45 qtrs — |
| 37 | BAMCO INC /NY/ | 1.21M -1.3M (-51.6%) | 71.01M -67.9M (-48.9%) | 0.77% -0.810 pp | 0.19% -0.176 pp | USD24.39 +141.1% | 45 qtrs — |
| 38 | MADISON ASSET MANAGEMENT, LLC | 1.18M +436.7K (+58.6%) | 69.47M +28.0M (+67.7%) | 0.76% +0.286 pp | 0.80% +0.342 pp | USD56.81 +3.5% | 2 qtrs — |
| 39 | SG CAPITAL MANAGEMENT LLC | 1.15M +1.1M (+100.0%) | 67.58M +67.6M (+100.0%) | 0.74% +0.737 pp | 6.49% +6.489 pp | USD58.81 +0.0% | 1 qtrs NEW |
| 40 | BANK OF AMERICA CORP /DE/ | 1.14M -41.8K (-3.5%) | 66.89M +1.3M (+2.0%) | 0.73% -0.019 pp | 0.00% +0.000 pp | USD67.01 -12.2% | 45 qtrs — |
| 41 | STEPHENS INVESTMENT MANAGEMENT GROUP LLC | 1.11M +94.5K (+9.3%) | 65.26M +8.8M (+15.6%) | 0.71% +0.068 pp | 0.85% +0.118 pp | USD53.71 +9.5% | 45 qtrs — |
| 42 | GENEVA CAPITAL MANAGEMENT LLC | 1.09M -94.5K (-8.0%) | 64.13M -1.8M (-2.7%) | 0.70% -0.053 pp | 1.20% +0.074 pp | USD51.17 +14.9% | 24 qtrs — |
| 43 | QUANTINNO CAPITAL MANAGEMENT LP | 1.02M -23.6K (-2.3%) | 59.95M +1.9M (+3.3%) | 0.65% -0.008 pp | 0.12% -0.038 pp | USD55.31 +6.3% | 17 qtrs — |
| 44 | FMR LLC | 1.01M +629.4K (+163.3%) | 59.69M +38.2M (+178.3%) | 0.65% +0.407 pp | 0.00% +0.002 pp | USD69.56 -15.5% | 30 qtrs — |
| 45 | WESTFIELD CAPITAL MANAGEMENT CO LP | 994.3K +994.3K (+100.0%) | 58.48M +58.5M (+100.0%) | 0.64% +0.638 pp | 0.24% +0.244 pp | USD58.81 +0.0% | 4 qtrs — |
| 46 | T. ROWE PRICE INVESTMENT MANAGEMENT, INC. | 979.4K -192.4K (-16.4%) | 57.60M -7.6M (-11.6%) | 0.63% -0.116 pp | 0.04% -0.004 pp | USD51.45 +14.3% | 3 qtrs — |
| 47 | CLEARBRIDGE INVESTMENTS, LLC | 948.5K -6.3K (-0.7%) | 55.78M +2.7M (+5.0%) | 0.61% +0.003 pp | 0.04% +0.005 pp | USD59.01 -0.3% | 24 qtrs — |
| 48 | AMERICAN CAPITAL MANAGEMENT INC | 941.1K -19.3K (-2.0%) | 55.35M +1.9M (+3.6%) | 0.60% -0.006 pp | 2.44% +0.314 pp | USD54.43 +8.0% | 45 qtrs — |
| 49 | SCHRODER INVESTMENT MANAGEMENT GROUP | 863.8K +863.8K (+100.0%) | 51.07M +51.1M (+100.0%) | 0.55% +0.554 pp | 0.04% +0.039 pp | USD58.81 +0.0% | 1 qtrs NEW |
| 50 | CITADEL ADVISORS LLC | 866.7K +649.5K (+299.1%) | 50.97M +38.9M (+321.9%) | 0.56% +0.418 pp | 0.01% +0.006 pp | USD58.11 +1.2% | 45 qtrs — |
| 51 | WEITZ INVESTMENT MANAGEMENT, INC. | 803.0K +800.0 (+0.1%) | 47.22M +2.6M (+5.8%) | 0.52% +0.006 pp | 2.80% +0.378 pp | USD64.91 -9.4% | 7 qtrs — |
| 52 | RIVERBRIDGE PARTNERS LLC | 785.8K -120.7K (-13.3%) | 46.21M -4.2M (-8.4%) | 0.50% -0.071 pp | 0.87% +0.016 pp | USD48.22 +22.0% | 46 qtrs — |
| 53 | JPMORGAN CHASE & CO | 759.1K +34.0K (+4.7%) | 44.64M +4.3M (+10.7%) | 0.49% +0.027 pp | 0.00% +0.000 pp | USD60.81 -3.3% | 45 qtrs — |
| 54 | NATIXIS ADVISORS, L.P. | 753.3K +611.9K (+432.8%) | 44.30M +36.4M (+463.3%) | 0.48% +0.394 pp | 0.06% +0.051 pp | USD61.10 -3.7% | 26 qtrs — |
| 55 | RAYMOND JAMES FINANCIAL INC | 746.8K +76.6K (+11.4%) | 44.05M +6.8M (+18.1%) | 0.48% +0.054 pp | 0.01% +0.002 pp | USD68.74 -14.4% | 5 qtrs — |
| 56 | PRINCIPAL FINANCIAL GROUP INC | 703.5K +534.7K (+316.7%) | 41.37M +32.0M (+340.6%) | 0.45% +0.345 pp | 0.02% +0.016 pp | USD57.06 +3.1% | 45 qtrs — |
| 57 | CRESSET ASSET MANAGEMENT, LLC | 693.6K +52.8K (+8.2%) | 40.79M +5.1M (+14.4%) | 0.45% +0.038 pp | 0.17% +0.021 pp | USD62.38 -5.7% | 21 qtrs — |
| 58 | CEREDEX VALUE ADVISORS LLC | 688.3K +688.3K (+100.0%) | 40.48M +40.5M (+100.0%) | 0.44% +0.442 pp | 1.22% +1.217 pp | USD58.81 +0.0% | 1 qtrs NEW |
| 59 | DEUTSCHE BANK AG\ | 684.0K -49.0K (-6.7%) | 40.23M -548.5K (-1.3%) | 0.44% -0.026 pp | 0.01% -0.001 pp | USD81.82 -28.1% | 45 qtrs — |
| 60 | ROYCE & ASSOCIATES LP | 678.5K +18.5K (+2.8%) | 39.90M +3.2M (+8.7%) | 0.44% +0.016 pp | 0.40% +0.039 pp | USD60.24 -2.4% | 45 qtrs — |
| 61 | CRAMER ROSENTHAL MCGLYNN LLC | 654.5K +95.3K (+17.0%) | 38.49M +7.4M (+23.7%) | 0.42% +0.065 pp | 2.48% +0.544 pp | USD70.14 -16.2% | 9 qtrs — |
| 62 | NUVEEN, LLC | 651.5K -299.3K (-31.5%) | 38.32M -14.6M (-27.6%) | 0.42% -0.186 pp | 0.01% -0.004 pp | USD55.13 +6.7% | 4 qtrs — |
| 63 | ARISTOTLE ATLANTIC PARTNERS, LLC | 636.8K -390.5K (-38.0%) | 37.45M -19.7M (-34.5%) | 0.41% -0.244 pp | 1.71% +0.056 pp | USD65.32 -10.0% | 32 qtrs — |
| 64 | GLENVIEW CAPITAL MANAGEMENT, LLC | 619.9K +245.9K (+65.7%) | 36.46M +15.7M (+75.2%) | 0.40% +0.160 pp | 0.74% +0.279 pp | USD56.89 +3.4% | 2 qtrs — |
| 65 | ROYAL BANK OF CANADA | 557.5K -172.5K (-23.6%) | 32.79M -7.8M (-19.3%) | 0.36% -0.106 pp | 0.01% -0.001 pp | USD53.81 +9.3% | 45 qtrs — |
| 66 | PEMBROKE MANAGEMENT, LTD | 512.9K +135.9K (+36.0%) | 30.16M +9.2M (+43.8%) | 0.33% +0.090 pp | 3.12% +1.035 pp | USD63.50 -7.4% | 22 qtrs — |
| 67 | PUBLIC EMPLOYEES RETIREMENT ASSOCIATION OF COLORADO | 507.2K +295.4K (+139.5%) | 29.83M +18.0M (+153.1%) | 0.33% +0.191 pp | 0.11% +0.066 pp | USD55.75 +5.5% | 45 qtrs — |
| 68 | SEGALL BRYANT & HAMILL, LLC | 486.0K -44.9K (-8.5%) | 28.58M -952.9K (-3.2%) | 0.31% -0.025 pp | 0.39% -0.007 pp | USD54.02 +8.9% | 46 qtrs — |
| 69 | IRON TRIANGLE PARTNERS LP | 467.4K +467.4K (+100.0%) | 27.49M +27.5M (+100.0%) | 0.30% +0.300 pp | 3.14% +3.143 pp | USD58.81 +0.0% | 1 qtrs NEW |
| 70 | SEI INVESTMENTS CO | 446.4K -116.5K (-20.7%) | 26.26M -5.1M (-16.2%) | 0.29% -0.071 pp | 0.03% -0.008 pp | USD62.62 -6.1% | 45 qtrs — |
| 71 | BROWN CAPITAL MANAGEMENT LLC | 435.6K -600.3K (-57.9%) | 25.62M -32.0M (-55.5%) | 0.28% -0.378 pp | 2.10% -0.274 pp | USD30.34 +93.8% | 45 qtrs — |
| 72 | UBS ASSET MANAGEMENT AMERICAS INC | 422.7K -133.3K (-24.0%) | 24.86M -6.1M (-19.6%) | 0.27% -0.082 pp | 0.01% -0.002 pp | USD82.98 -29.1% | 45 qtrs — |
| 73 | CAPTION MANAGEMENT, LLC | 402.2K +284.7K (+242.3%) | 23.65M +17.1M (+261.9%) | 0.26% +0.184 pp | 0.16% +0.111 pp | USD57.88 +1.6% | 2 qtrs — |
| 74 | NICHOLAS COMPANY, INC. | 390.8K +23.8K (+6.5%) | 22.98M +2.6M (+12.6%) | 0.25% +0.018 pp | 0.40% +0.056 pp | USD66.51 -11.6% | 11 qtrs — |
| 75 | EVERSEPT PARTNERS, LP | 377.4K -214.1K (-36.2%) | 22.20M -10.7M (-32.6%) | 0.24% -0.133 pp | 1.12% -1.149 pp | USD64.48 -8.8% | 13 qtrs — |
| 76 | ADAGE CAPITAL PARTNERS GP, L.L.C. | 373.2K +230.5K (+161.6%) | 21.95M +14.0M (+176.5%) | 0.24% +0.149 pp | 0.03% +0.021 pp | USD65.82 -10.7% | 6 qtrs — |
| 77 | PALO DS MANAGER LLC | 355.5K -15.1K (-4.1%) | 20.91M +290.9K (+1.4%) | 0.23% -0.007 pp | 7.24% -0.156 pp | USD55.15 +6.6% | 4 qtrs — |
| 78 | CONESTOGA CAPITAL ADVISORS, LLC | 354.6K +49.1K (+16.1%) | 20.85M +3.9M (+22.7%) | 0.23% +0.034 pp | 0.35% +0.078 pp | USD50.07 +17.5% | 45 qtrs — |
| 79 | ATOM INVESTORS LP | 351.7K +351.7K (+100.0%) | 20.68M +20.7M (+100.0%) | 0.23% +0.226 pp | 1.64% +1.642 pp | USD58.81 +0.0% | 1 qtrs NEW |
| 80 | MONTANARO ASSET MANAGEMENT LTD | 346.5K -15.6K (-4.3%) | 20.37M +233.9K (+1.2%) | 0.22% -0.008 pp | 5.68% +0.648 pp | USD83.87 -29.9% | 20 qtrs — |
| 81 | FORT WASHINGTON INVESTMENT ADVISORS INC /OH/ | 327.6K -146.8K (-30.9%) | 19.26M -7.1M (-27.0%) | 0.21% -0.091 pp | 0.10% -0.040 pp | USD61.35 -4.1% | 33 qtrs — |
| 82 | BI ASSET MANAGEMENT FONDSMAEGLERSELSKAB A/S | 323.8K +18.7K (+6.1%) | 19.04M +2.1M (+12.2%) | 0.21% +0.014 pp | 0.17% +0.015 pp | USD69.28 -15.1% | 15 qtrs — |
| 83 | CI INVESTMENTS INC. | 323.1K +319.0K (+7,871.1%) | 19.00M +18.8M (+8,344.3%) | 0.21% +0.205 pp | 0.08% +0.082 pp | USD59.05 -0.4% | 22 qtrs — |
| 84 | STATE FARM MUTUAL AUTOMOBILE INSURANCE CO | 321.4K +— (+0.0%) | 18.90M +1.0M (+5.7%) | 0.21% +0.002 pp | 0.01% 0.000 pp | USD23.10 +154.6% | 45 qtrs — |
| 85 | SWISS NATIONAL BANK | 307.0K +3.2K (+1.1%) | 18.05M +1.2M (+6.8%) | 0.20% +0.004 pp | 0.01% +0.001 pp | USD73.37 -19.8% | 45 qtrs — |
| 86 | ARVIN CAPITAL MANAGEMENT LP | 299.5K +299.5K (+100.0%) | 17.62M +17.6M (+100.0%) | 0.19% +0.192 pp | 3.32% +3.317 pp | USD58.81 +0.0% | 3 qtrs — |
| 87 | LORD, ABBETT & CO. LLC | 297.4K +36.5K (+14.0%) | 17.49M +3.0M (+20.5%) | 0.19% +0.025 pp | 0.05% +0.011 pp | USD59.82 -1.7% | 27 qtrs — |
| 88 | BNP PARIBAS ARBITRAGE, SNC | 285.2K +34.3K (+13.7%) | 16.77M +2.8M (+20.1%) | 0.18% +0.024 pp | 0.01% +0.000 pp | USD67.22 -12.5% | 45 qtrs — |
| 89 | SUMMIT CREEK ADVISORS LLC | 282.6K -21.1K (-7.0%) | 16.62M -277.7K (-1.6%) | 0.18% -0.011 pp | 2.61% +0.152 pp | USD53.62 +9.7% | 45 qtrs — |
| 90 | CI PRIVATE WEALTH, LLC | 279.8K -198.4K (-41.5%) | 16.53M -10.1M (-37.8%) | 0.18% -0.124 pp | 0.02% -0.020 pp | USD72.65 -19.1% | 13 qtrs — |
| 91 | RHUMBLINE ADVISERS | 281.1K -20.1K (-6.7%) | 16.53M -223.6K (-1.3%) | 0.18% -0.011 pp | 0.01% 0.000 pp | USD43.23 +36.0% | 46 qtrs — |
| 92 | ENVESTNET ASSET MANAGEMENT INC | 280.0K -5.6K (-2.0%) | 16.47M +578.9K (+3.6%) | 0.18% -0.002 pp | 0.00% +0.000 pp | USD67.16 -12.4% | 43 qtrs — |
| 93 | BARCLAYS PLC | 277.0K -55.1K (-16.6%) | 16.29M -10.3M (-38.6%) | 0.18% -0.033 pp | 0.00% -0.003 pp | USD80.67 -27.1% | 45 qtrs — |
| 94 | CALIFORNIA PUBLIC EMPLOYEES RETIREMENT SYSTEM | 270.9K +13.0K (+5.0%) | 15.93M +1.6M (+11.0%) | 0.17% +0.010 pp | 0.01% +0.001 pp | USD48.89 +20.3% | 45 qtrs — |
| 95 | THRIVENT FINANCIAL FOR LUTHERANS | 269.2K +43.4K (+19.2%) | 15.83M +3.3M (+26.0%) | 0.17% +0.030 pp | 0.03% +0.003 pp | USD76.77 -23.4% | 45 qtrs — |
| 96 | VAN ECK ASSOCIATES CORP | 263.9K +30.6K (+13.1%) | 15.52M +2.5M (+19.6%) | 0.17% +0.021 pp | 0.01% +0.001 pp | USD78.14 -24.7% | 20 qtrs — |
| 97 | LEGAL & GENERAL GROUP PLC | 263.8K -59.3K (-18.3%) | 15.52M -2.5M (-13.7%) | 0.17% -0.036 pp | 0.00% -0.001 pp | USD92.95 -36.7% | 45 qtrs — |
| 98 | CITIGROUP INC | 258.4K +61.0K (+30.9%) | 15.20M +4.2M (+38.4%) | 0.17% +0.041 pp | 0.01% +0.002 pp | USD62.13 -5.3% | 45 qtrs — |
| 99 | BORDER TO COAST PENSIONS PARTNERSHIP LTD | 255.0K +255.0K (+100.0%) | 15.02M +15.0M (+100.0%) | 0.16% +0.164 pp | 0.26% +0.262 pp | USD58.81 +0.0% | 1 qtrs NEW |
Ownership breakdown by holder
Insider Activity
Insider Activity — Latest Quarter
Ratio by transactions
0.50
Neutral
Ratio by volume
0.55
Neutral
Buys
4
Sells
8
Shares acquired
112.1K
Shares disposed
202.4K
Cash buys
—
Cash sales
—
Net activity
-90,288
Insider buys vs sells (history)
From
To
Recent insider transactions
From
To
| Date | Person | Role | Transaction | A/D | Security | Shares | Price | Value | Owned after | D/I | Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-05-01 | Crouse Steven C. | Officer | M-Exempt | A | Common Stock | 794 | 0.00 | — | 6,688 | D | ↗ |
| 2026-04-22 | Kelderman Kim | Director / Officer | M-Exempt | A | Common Stock | 11,344 | 0.00 | — | 64,421 | D | ↗ |
| 2026-04-22 | Hippel James | Officer | M-Exempt | A | Common Stock | 62,000 | 0.00 | — | 204,722 | D | ↗ |
| 2026-04-14 | Kelderman Kim | Director / Officer | F-InKind | D | Common Stock | 32,088 | 58.66 | 1.88M | 53,077 | D | ↗ |
| 2026-04-03 | Bohnen Shane | Officer | M-Exempt | A | Common Stock | 2,259 | 0.00 | — | 6,644 | D | ↗ |
| 2026-03-02 | Crouse Steven C. | Officer | A-Award | A | Performance Restricted Stock Units | 2,387 | 0.00 | — | 2,387 | D | ↗ |
| 2026-03-01 | Crouse Steven C. | Officer | — | — | Stock Option (right to buy) | 17,133 | 74.91 | 1.28M | 0 | D | ↗ |
| 2026-02-17 | Herr Amy E. | Director | S-Sale | D | Common Stock | 1,976 | 59.11 | 116.8K | 200 | I | ↗ |
| 2026-02-03 | Herr Amy E. | Director | M-Exempt | A | Common Stock | 38 | 0.00 | — | 2,192 | I | ↗ |
| 2026-02-01 | McManus Matthew | Officer | M-Exempt | A | Common Stock | 4,621 | 0.00 | — | 9,356 | D | ↗ |
| 2025-11-03 | Kelderman Kim | Director / Officer | F-InKind | D | Common Stock | 2,303 | 62.57 | 144.1K | 48,665 | D | ↗ |
| 2025-11-03 | Hippel James | Officer | M-Exempt | D | Restricted Stock Units | 11,545 | 0.00 | — | 23,089 | D | ↗ |
| 2025-11-03 | Geist William | Officer | M-Exempt | D | Restricted Stock Units | 9,911 | 0.00 | — | 0 | D | ↗ |
| 2025-10-30 | Vessey Rupert | Director | A-Award | A | Stock Options (Right to Buy) | 3,777 | 60.96 | 230.2K | 3,777 | D | ↗ |
| 2025-10-30 | Seth Alpna | Director | A-Award | A | Stock Options (Right to Buy) | 3,777 | 60.96 | 230.2K | 3,777 | D | ↗ |
| 2025-10-30 | Klimovsky Judith V. | Director | A-Award | A | Stock Option (Right to Buy) | 3,777 | 60.96 | 230.2K | 3,777 | D | ↗ |
| 2025-10-30 | KEEGAN JOSEPH D | Director | A-Award | A | Stock Options (Right to Buy) | 3,777 | 60.96 | 230.2K | 3,777 | D | ↗ |
| 2025-10-30 | Herr Amy E. | Director | A-Award | A | Common Stock | 1,640 | 0.00 | — | 2,680 | D | ↗ |
| 2025-10-30 | HIGGINS JOHN L | Director | A-Award | A | Stock Options (Right to Buy) | 3,777 | 60.96 | 230.2K | 3,777 | D | ↗ |
| 2025-10-30 | Bushman Julie L | Director | A-Award | A | Stock Options (Right to Buy) | 3,777 | 60.96 | 230.2K | 3,777 | D | ↗ |
| 2025-10-30 | BAUMGARTNER ROBERT V | Director | A-Award | A | Stock Options (Right to Buy) | 3,777 | 60.96 | 230.2K | 3,777 | D | ↗ |
| 2025-08-25 | Nusse Roeland | Director | M-Exempt | A | Common Stock | 17,040 | 21.84 | 372.2K | 61,599 | D | ↗ |
| 2025-08-25 | BAUMGARTNER ROBERT V | Director | M-Exempt | A | Common Stock | 17,040 | 21.84 | 372.2K | 61,903 | D | ↗ |
| 2025-08-15 | McManus Matthew | Officer | A-Award | A | Stock Option (Right to Buy) | 24,614 | 53.60 | 1.32M | 24,614 | D | ↗ |
| 2025-08-15 | Kelderman Kim | Director / Officer | A-Award | A | Stock Options (Right to Buy) | 90,441 | 53.60 | 4.85M | 90,441 | D | ↗ |
| 2025-08-15 | Hippel James | Officer | M-Exempt | A | Common Stock | 4,010 | 0.00 | — | 131,809 | D | ↗ |
| 2025-08-15 | Herr Amy E. | Director | M-Exempt | D | Restricted Stock Units | 119 | 0.00 | — | 118 | I | ↗ |
| 2025-08-15 | Geist William | Officer | M-Exempt | A | Common Stock | 2,623 | 0.00 | — | 15,915 | D | ↗ |
| 2025-08-15 | Bohnen Shane | Officer | M-Exempt | D | Restricted Stock Units | 1,668 | 0.00 | — | 3,338 | D | ↗ |
| 2025-08-07 | HIGGINS JOHN L | Director | M-Exempt | A | Common Stock | 5,040 | 21.84 | 110.1K | 65,236 | D | ↗ |
| 2025-07-29 | Hippel James | Officer | M-Exempt | D | Stock Options (Right to Buy) | 168,620 | 44.33 | 7.47M | 0 | D | ↗ |
| 2025-07-22 | Kelderman Kim | Director / Officer | M-Exempt | A | Common Stock | 48,176 | 44.33 | 2.14M | 90,379 | D | ↗ |
| 2025-07-15 | Kelderman Kim | Director / Officer | M-Exempt | A | Common Stock | 36,132 | 44.33 | 1.60M | 75,136 | D | ↗ |
| 2025-06-09 | Herr Amy E. | Director | M-Exempt | A | Common Stock | 1,280 | 44.33 | 56.7K | 3,256 | I | ↗ |
| 2025-05-01 | HIGGINS JOHN L | Director | M-Exempt | A | Common Stock | 12,000 | 21.84 | 262.1K | 60,196 | D | ↗ |
| 2025-04-03 | Bohnen Shane | Officer | M-Exempt | A | Common Stock | 2,260 | 0.00 | — | 3,941 | D | ↗ |
| 2025-02-14 | Herr Amy E. | Director | M-Exempt | A | Common Stock | 1,976 | 44.33 | 87.6K | 3,836 | I | ↗ |
| 2025-02-03 | Herr Amy E. | Director | A-Award | A | Stock Option (Right to Buy) | 2,415 | 72.05 | 174.0K | 2,415 | D | ↗ |
| 2025-02-01 | McManus Matthew | Officer | M-Exempt | A | Common Stock | 4,620 | 0.00 | — | 4,620 | D | ↗ |
| 2025-02-01 | Herr Amy E. | Director | — | — | Stock Option (Right to Buy) | 1,084 | 84.61 | 91.7K | 0 | I | ↗ |
| 2025-02-01 | Geist William | Officer | M-Exempt | A | Common Stock | 3,320 | 0.00 | — | 14,401 | D | ↗ |
| 2025-01-27 | Kelderman Kim | Director / Officer | S-Sale | D | Common Stock | 11,731 | 77.19 | 905.5K | 40,665 | D | ↗ |
| 2024-11-01 | Kelderman Kim | Director / Officer | F-InKind | D | Common Stock | 2,430 | 75.31 | 183.0K | 39,004 | D | ↗ |
| 2024-11-01 | Hippel James | Officer | M-Exempt | A | Common Stock | 13,159 | 0.00 | — | 113,085 | D | ↗ |
| 2024-11-01 | Geist William | Officer | M-Exempt | A | Common Stock | 9,912 | 0.00 | — | 14,351 | D | ↗ |
| 2024-10-24 | VESSEY RUPERT | Director | A-Award | A | Common Stock | 1,462 | 0.00 | — | 9,347 | D | ↗ |
| 2024-10-24 | Seth Alpna | Director | A-Award | A | Common Stock | 1,462 | 0.00 | — | 13,771 | D | ↗ |
| 2024-10-24 | Nusse Roeland | Director | A-Award | A | Common Stock | 1,462 | 0.00 | — | 44,559 | D | ↗ |
| 2024-10-24 | Klimovsky Judith V | Director | A-Award | A | Stock Option (Right to Buy) | 3,511 | 68.37 | 240.0K | 3,511 | D | ↗ |
| 2024-10-24 | KEEGAN JOSEPH D | Director | A-Award | A | Stock Options (Right to Buy) | 3,511 | 68.37 | 240.0K | 3,511 | D | ↗ |
| 2024-10-24 | HIGGINS JOHN L | Director | A-Award | A | Stock Options (Right to Buy) | 3,511 | 68.37 | 240.0K | 3,511 | D | ↗ |
| 2024-10-24 | Bushman Julie L | Director | A-Award | A | Common Stock | 1,462 | 0.00 | — | 7,135 | D | ↗ |
| 2024-10-24 | BAUMGARTNER ROBERT V | Director | A-Award | A | Common Stock | 1,462 | 0.00 | — | 44,863 | D | ↗ |
| 2024-09-12 | HIGGINS JOHN L | Director | M-Exempt | A | Common Stock | 6,000 | 22.95 | 137.7K | 48,608 | — | ↗ |
| 2024-08-29 | Kelderman Kim | Director / Officer | M-Exempt | D | Stock Option (Right to Buy) | 1,492 | 66.97 | 99.9K | 115,724 | — | ↗ |
| 2024-08-15 | McManus Matthew | Officer | A-Award | A | Restricted Stock Units | 7,912 | 0.00 | — | 7,912 | — | ↗ |
| 2024-08-15 | Kelderman Kim | Director / Officer | A-Award | A | Restricted Stock Units | 25,630 | 0.00 | — | 25,630 | — | ↗ |
| 2024-08-15 | Hippel James | Officer | A-Award | A | Restricted Stock Units | 12,031 | 0.00 | — | 12,031 | — | ↗ |
| 2024-08-15 | Geist William | Officer | A-Award | A | Restricted Stock Units | 7,869 | 0.00 | — | 7,869 | — | ↗ |
| 2024-08-15 | Bohnen Shane | Officer | M-Exempt | D | Restricted Stock Units | 49 | 0.00 | — | 99 | — | ↗ |
| 2024-08-08 | BAUMGARTNER ROBERT V | Director | S-Sale | D | Common Stock | 16,000 | 72.10 | 1.15M | 43,401 | — | ↗ |
| 2024-08-02 | Hippel James | Officer | M-Exempt | A | Common Stock | 53,000 | 31.26 | 1.66M | 136,002 | — | ↗ |
| 2024-07-31 | Kelderman Kim | Director / Officer | M-Exempt | A | Common Stock | 14,000 | 37.70 | 527.8K | 49,421 | — | ↗ |
| 2024-07-23 | Hippel James | Officer | M-Exempt | A | Common Stock | 35,000 | 31.26 | 1.09M | 107,284 | — | ↗ |
| 2024-07-08 | HIGGINS JOHN L | Director | M-Exempt | A | Common Stock | 6,000 | 22.95 | 137.7K | 42,608 | — | ↗ |
| 2024-05-14 | HIGGINS JOHN L | Director | S-Sale | D | Common Stock | 4,000 | 83.84 | 335.4K | 36,608 | — | ↗ |
| 2024-05-01 | Klimovsky Judith V | Director | A-Award | A | Stock Option (Right to Buy) | 1,610 | 73.46 | 118.3K | 1,610 | — | ↗ |
| 2024-04-24 | Klimovsky Judith V | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2024-04-03 | Bohnen Shane | Officer | M-Exempt | D | Restricted Stock Units | 2,259 | 0.00 | — | 4,519 | — | ↗ |
| 2024-03-07 | Nusse Roeland | Director | S-Sale | D | Common Stock | 10,400 | 76.98 | 800.6K | 43,097 | — | ↗ |
| 2024-02-01 | McManus Matthew | Officer | A-Award | A | Restricted Stock Units | 2,888 | 0.00 | — | 2,888 | — | ↗ |
| 2024-02-01 | Kelderman Kim | Officer | A-Award | A | Stock Options (Right to Buy) | 51,890 | 68.54 | 3.56M | 51,890 | — | ↗ |
| 2024-02-01 | Geist William | Officer | F-InKind | D | Common Stock | 1,111 | 68.54 | 76.1K | 7,759 | — | ↗ |
| 2024-01-08 | McManus Matthew | Officer | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2023-12-19 | Hippel James | Officer | F-InKind | D | Common Stock | 32,966 | 77.42 | 2.55M | 71,884 | — | ↗ |
| 2023-11-01 | Kelderman Kim | Officer | A-Award | A | Common Stock | 14,196 | 0.00 | — | 35,421 | — | ↗ |
| 2023-11-01 | Hippel James | Officer | A-Award | A | Restricted Stock Units | 26,318 | 0.00 | — | 26,318 | — | ↗ |
| 2023-11-01 | Geist William | Officer | A-Award | A | Restricted Stock Units | 19,823 | 0.00 | — | 19,823 | — | ↗ |
| 2023-10-26 | VESSEY RUPERT | Director | A-Award | A | Stock Options (Right to Buy) | 3,937 | 61.51 | 242.2K | 3,937 | — | ↗ |
| 2023-10-26 | Seth Alpna | Director | A-Award | A | Stock Options (Right to Buy) | 3,937 | 61.51 | 242.2K | 3,937 | — | ↗ |
| 2023-10-26 | STEER RANDOLPH C | Director | A-Award | A | Stock Options (Right to Buy) | 3,937 | 61.51 | 242.2K | 3,937 | — | ↗ |
| 2023-10-26 | Nusse Roeland | Director | A-Award | A | Common Stock | 1,625 | 0.00 | — | 53,497 | — | ↗ |
| 2023-10-26 | KEEGAN JOSEPH D | Director | A-Award | A | Common Stock | 1,625 | 0.00 | — | 12,309 | — | ↗ |
| 2023-10-26 | HIGGINS JOHN L | Director | A-Award | A | Common Stock | 1,625 | 0.00 | — | 36,608 | — | ↗ |
| 2023-10-26 | Bushman Julie L | Director | A-Award | A | Common Stock | 1,625 | 0.00 | — | 5,673 | — | ↗ |
| 2023-10-26 | BAUMGARTNER ROBERT V | Director | A-Award | A | Common Stock | 1,625 | 0.00 | — | 43,401 | — | ↗ |
| 2023-08-30 | Nusse Roeland | Director | M-Exempt | A | Common Stock | 16,000 | 22.95 | 367.2K | 60,811 | — | ↗ |
| 2023-08-24 | Kelderman Kim | Officer | M-Exempt | D | Stock Option (Right to Buy) | 2,100 | 47.60 | 100.0K | 109,536 | — | ↗ |
| 2023-08-15 | Kummeth Charles R. | Director / Officer | M-Exempt | A | Common Stock | 17,632 | 0.00 | — | 1,286,944 | — | ↗ |
| 2023-08-15 | Kelderman Kim | Officer | A-Award | A | Restricted Stock Units | 8,191 | 0.00 | — | 8,191 | — | ↗ |
| 2023-08-15 | Hippel James | Officer | A-Award | A | Restricted Stock Units | 12,798 | 0.00 | — | 12,798 | — | ↗ |
| 2023-08-15 | Geist William | Officer | A-Award | A | Stock Options (Right to Buy) | 30,059 | 84.61 | 2.54M | 30,059 | — | ↗ |
| 2023-08-15 | Bohnen Shane | Officer | A-Award | A | Stock Option (Right to Buy) | 11,928 | 84.61 | 1.01M | 11,928 | — | ↗ |
| 2023-08-09 | Kummeth Charles R. | Director / Officer | G-Gift | D | Common Stock | 9,008 | 0.00 | — | 1,269,312 | — | ↗ |
| 2023-08-05 | Kummeth Charles R. | Director / Officer | M-Exempt | A | Common Stock | 51,516 | 0.00 | — | 1,310,282 | — | ↗ |
| 2023-08-05 | Kelderman Kim | Officer | M-Exempt | A | Common Stock | 8,060 | 0.00 | — | 23,264 | — | ↗ |
| 2023-08-05 | Hippel James | Officer | M-Exempt | A | Common Stock | 12,876 | 0.00 | — | 63,896 | — | ↗ |
| 2023-07-21 | Kummeth Charles R. | Director / Officer | S-Sale | D | Common Stock | 80,000 | 88.36 | 7.07M | 1,258,766 | — | ↗ |
| 2023-06-30 | Kummeth Charles R. | Director / Officer | M-Exempt | D | Stock Options (Right to Buy) | 616,676 | 26.65 | 16.43M | 0 | — | ↗ |
| 2023-06-07 | Kummeth Charles R. | Director / Officer | S-Sale | D | Common Stock | 322 | 83.00 | 26.7K | 1,112,817 | — | ↗ |
| 2023-04-28 | HIGGINS JOHN L | Director | M-Exempt | A | Common Stock | 16,000 | 21.85 | 349.6K | 39,360 | — | ↗ |
| 2023-04-19 | Nusse Roeland | Director | G-Gift | D | Common Stock | 377 | 0.00 | — | 28,811 | — | ↗ |
| 2023-04-03 | Bohnen Shane | Officer | A-Award | A | Restricted Stock Units | 6,778 | 0.00 | — | 6,778 | — | ↗ |
| 2023-03-03 | Bohnen Shane | Officer | — | D | Stock Option (right to buy) | 3,508 | 94.52 | 331.6K | 0 | — | ↗ |
| 2023-01-04 | Kummeth Charles R. | Officer | M-Exempt | A | Common Stock | 407,364 | 26.65 | 10.86M | 1,368,976 | — | ↗ |
| 2022-12-08 | Furlow Brenda S. | Director | M-Exempt | A | Common Stock | 7,450 | 31.26 | 232.9K | 33,542 | — | ↗ |
| 2022-12-07 | Furlow Brenda S. | Director | M-Exempt | D | Stock Options (Right to Buy) | 800 | 0.00 | — | 37,212 | — | ↗ |
| 2022-10-27 | VESSEY RUPERT | Director | A-Award | A | Stock Options (Right to Buy) | 865 | 0.00 | — | 865 | — | ↗ |
| 2022-10-27 | Seth Alpna | Director | A-Award | A | Common Stock | 338 | 0.00 | — | 2,671 | — | ↗ |
| 2022-10-27 | STEER RANDOLPH C | Director | A-Award | A | Common Stock | 338 | 0.00 | — | 5,644 | — | ↗ |
| 2022-10-27 | Nusse Roeland | Director | A-Award | A | Stock Options (Right to Buy) | 865 | 0.00 | — | 865 | — | ↗ |
| 2022-10-27 | KEEGAN JOSEPH D | Director | A-Award | A | Common Stock | 338 | 0.00 | — | 2,671 | — | ↗ |
| 2022-10-27 | HIGGINS JOHN L | Director | A-Award | A | Common Stock | 338 | 0.00 | — | 5,840 | — | ↗ |
| 2022-10-27 | Bushman Julie L | Director | A-Award | A | Stock Options (Right to Buy) | 865 | 0.00 | — | 865 | — | ↗ |
| 2022-10-27 | BAUMGARTNER ROBERT V | Director | A-Award | A | Stock Options (Right to Buy) | 865 | 0.00 | — | 865 | — | ↗ |
| 2022-08-23 | Kelderman Kim | Officer | M-Exempt | D | Stock Option (Right to Buy) | 663 | 0.00 | — | 6,848 | — | ↗ |
| 2022-08-15 | Kummeth Charles R. | Director / Officer | A-Award | A | Stock Options (Right to Buy) | 300,000 | 378.08 | 113.42M | 300,000 | — | ↗ |
| 2022-08-15 | Kelderman Kim | Director | A-Award | A | Stock Options (Right to Buy) | 5,426 | 0.00 | — | 5,426 | — | ↗ |
| 2022-08-15 | Hippel James | Officer | A-Award | A | Stock Options (Right to Buy) | 11,305 | 378.08 | 4.27M | 11,305 | — | ↗ |
| 2022-08-15 | Geist William | Officer | A-Award | A | Stock Options (Right to Buy) | 7,400 | 378.08 | 2.80M | 7,400 | — | ↗ |
| 2022-08-15 | Furlow Brenda S. | Officer | A-Award | A | Restricted Stock Units | 1,984 | 0.00 | — | 1,984 | — | ↗ |
| 2022-08-10 | HIGGINS JOHN L | Director | M-Exempt | D | Stock Option (right to buy) | 3,400 | 0.00 | — | 0 | — | ↗ |
| 2022-08-08 | Furlow Brenda S. | Officer | M-Exempt | D | Stock Options (Right to Buy) | 563 | 177.32 | 99.8K | 16,562 | — | ↗ |
| 2022-08-07 | Kummeth Charles R. | Officer | M-Exempt | D | Restricted Stock Units | 16,937 | 0.00 | — | 0 | — | ↗ |
| 2022-08-07 | Kelderman Kim | Officer | M-Exempt | D | Restricted Stock Units | 2,363 | 0.00 | — | 0 | — | ↗ |
| 2022-08-07 | Hippel James | Officer | M-Exempt | D | Restricted Stock Units | 3,938 | 0.00 | — | 0 | — | ↗ |
| 2022-08-07 | Furlow Brenda S. | Officer | G-Gift | A | Common Stock | 1,330 | 0.00 | — | 1,330 | — | ↗ |
| 2022-07-28 | Kummeth Charles R. | Director / Officer | M-Exempt | A | Common Stock | 45,346 | 108.49 | 4.92M | 262,749 | — | ↗ |
| 2022-07-06 | Kummeth Charles R. | Director / Officer | M-Exempt | D | Stock Option (right to buy) | 50,000 | 0.00 | — | 45,346 | — | ↗ |
| 2022-06-07 | Kummeth Charles R. | Director / Officer | M-Exempt | A | Common Stock | 5,104 | 108.49 | 553.7K | 203,442 | — | ↗ |
| 2022-06-07 | HIGGINS JOHN L | Director | S-Sale | D | Common Stock | 1,000 | 364.31 | 364.3K | 4,606 | — | ↗ |
| 2022-05-10 | BAUMGARTNER ROBERT V | Director | P-Purchase | A | Common Stock | 300 | 352.55 | 105.8K | 10,106 | — | ↗ |
| 2022-02-08 | Kelderman Kim | Officer | M-Exempt | D | Stock Option (Right to Buy) | 1,989 | 150.78 | 299.9K | 7,511 | — | ↗ |
| 2022-02-01 | Geist William | Officer | A-Award | A | Restricted Stock Units | 840 | 0.00 | — | 840 | — | ↗ |
| 2022-01-28 | Kummeth Charles R. | Director / Officer | M-Exempt | D | Stock Options (Right to Buy) | 938 | 106.59 | 100.0K | 256,010 | — | ↗ |
| 2022-01-03 | Geist William | Officer | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2021-11-19 | Kelderman Kim | Officer | M-Exempt | D | Stock Option (Right to Buy) | 500 | 150.78 | 75.4K | 2,152 | — | ↗ |
| 2021-11-16 | Eansor Norman David | Officer | M-Exempt | D | Stock Options (Right to Buy) | 799 | 125.05 | 99.9K | 0 | — | ↗ |
| 2021-11-12 | Eansor Norman David | Officer | M-Exempt | D | Stock Options (Right to Buy) | 27,159 | 125.05 | 3.40M | 799 | — | ↗ |
| 2021-11-02 | Hippel James | Officer | S-Sale | D | Common Stock | 200 | 525.10 | 105.0K | 10,755 | — | ↗ |
| 2021-11-01 | Hippel James | Officer | S-Sale | D | Common Stock | 943 | 528.55 | 498.4K | 10,755 | — | ↗ |
| 2021-10-29 | Hippel James | Officer | S-Sale | D | Common Stock | 662 | 525.23 | 347.7K | 10,755 | — | ↗ |
| 2021-10-28 | VESSEY RUPERT | Director | A-Award | A | Stock Option (right to buy) | 633 | 515.24 | 326.1K | 633 | — | ↗ |
| 2021-10-28 | Seth Alpna | Director | A-Award | A | Common Stock | 194 | 0.00 | — | 2,333 | — | ↗ |
| 2021-10-28 | STEER RANDOLPH C | Director | A-Award | A | Stock Option (right to buy) | 633 | 515.24 | 326.1K | 633 | — | ↗ |
| 2021-10-28 | Nusse Roeland | Director | A-Award | A | Stock Option (right to buy) | 633 | 515.24 | 326.1K | 633 | — | ↗ |
| 2021-10-28 | KEEGAN JOSEPH D | Director | A-Award | A | Common Stock | 194 | 0.00 | — | 2,333 | — | ↗ |
| 2021-10-28 | Hippel James | Officer | S-Sale | D | Common Stock | 100 | 525.18 | 52.5K | 10,755 | — | ↗ |
| 2021-10-28 | HIGGINS JOHN L | Director | A-Award | A | Stock Option (right to buy) | 633 | 515.24 | 326.1K | 633 | — | ↗ |
| 2021-10-28 | Bushman Julie L | Director | A-Award | A | Stock Option (right to buy) | 633 | 515.24 | 326.1K | 633 | — | ↗ |
| 2021-10-28 | BAUMGARTNER ROBERT V | Director | A-Award | A | Stock Options (right to buy) | 633 | 515.24 | 326.1K | 633 | — | ↗ |
| 2021-10-26 | Furlow Brenda S. | Officer | G-Gift | D | Common Stock | 1,330 | 0.00 | — | 6,290 | — | ↗ |
| 2021-09-22 | Kelderman Kim | Officer | S-Sale | D | Common Stock | 822 | 529.04 | 434.9K | 0 | — | ↗ |
| 2021-09-07 | STEER RANDOLPH C | Director | M-Exempt | A | Common Stock | 4,000 | 91.78 | 367.1K | 13,112 | — | ↗ |
| 2021-09-02 | Kummeth Charles R. | Director / Officer | M-Exempt | D | Stock Options (Right to Buy) | 73,492 | 108.49 | 7.97M | 100,450 | — | ↗ |
| 2021-09-02 | Hippel James | Officer | M-Exempt | D | Stock Options (Right to Buy) | 10,000 | 106.59 | 1.07M | 0 | — | ↗ |
| 2021-09-02 | Furlow Brenda S. | Officer | S-Sale | D | Common Stock | 1,576 | 510.82 | 805.1K | 7,620 | — | ↗ |
| 2021-08-31 | Furlow Brenda S. | Officer | S-Sale | D | Common Stock | 3,108 | 506.12 | 1.57M | 7,620 | — | ↗ |
| 2021-08-31 | Eansor Norman David | Officer | S-Sale | D | Common Stock | 1,538 | 503.07 | 773.7K | 1,318 | — | ↗ |
| 2021-08-23 | Nusse Roeland | Director | M-Exempt | A | Common Stock | 4,000 | 70.35 | 281.4K | 10,765 | — | ↗ |
| 2021-08-23 | BAUMGARTNER ROBERT V | Director | S-Sale | D | Common Stock | 601 | 483.60 | 290.6K | 12,712 | — | ↗ |
| 2021-08-19 | Furlow Brenda S. | Officer | M-Exempt | D | Stock Options (Right to Buy) | 3,538 | 106.59 | 377.1K | 0 | — | ↗ |
| 2021-08-11 | Kummeth Charles R. | Director / Officer | M-Exempt | D | Stock Options (Right to Buy) | 921 | 108.49 | 99.9K | 173,942 | — | ↗ |
| 2021-08-09 | Hippel James | Officer | S-Sale | D | Common Stock | 5,200 | 477.69 | 2.48M | 15,655 | — | ↗ |
| 2021-08-08 | Kelderman Kim | Officer | M-Exempt | A | Common Stock | 1,691 | 0.00 | — | 1,691 | — | ↗ |
| 2021-08-08 | Hippel James | Officer | M-Exempt | D | Restricted Stock Units | 3,383 | 0.00 | — | 0 | — | ↗ |
| 2021-08-08 | Furlow Brenda S. | Officer | M-Exempt | D | Restricted Stock Units | 1,374 | 0.00 | — | 0 | — | ↗ |
| 2021-08-08 | Eansor Norman David | Officer | M-Exempt | D | Restricted Stock Units | 2,537 | 0.00 | — | 0 | — | ↗ |
| 2021-08-06 | Kummeth Charles R. | Director / Officer | A-Award | A | Restricted Stock Units | 8,016 | 0.00 | — | 8,016 | — | ↗ |
| 2021-08-06 | Kelderman Kim | Officer | A-Award | A | Restricted Stock Units | 1,245 | 0.00 | — | 1,245 | — | ↗ |
| 2021-08-06 | Hippel James | Officer | A-Award | A | Stock Options (Right to Buy) | 7,600 | 481.82 | 3.66M | 7,600 | — | ↗ |
| 2021-08-06 | Furlow Brenda S. | Officer | A-Award | A | Restricted Stock Units | 1,167 | 0.00 | — | 1,167 | — | ↗ |
| 2021-08-06 | Eansor Norman David | Officer | A-Award | A | Restricted Stock Units | 1,556 | 0.00 | — | 1,556 | — | ↗ |
| 2021-07-12 | Hippel James | Officer | S-Sale | D | Common Stock | 527 | 456.41 | 240.5K | 14,036 | — | ↗ |
| 2021-06-18 | Kummeth Charles R. | Director / Officer | S-Sale | D | Common Stock | 2,583 | 449.09 | 1.16M | 154,732 | — | ↗ |
| 2021-06-17 | Kummeth Charles R. | Director / Officer | S-Sale | D | Common Stock | 1,698 | 450.39 | 764.8K | 158,474 | — | ↗ |
| 2021-06-14 | Kummeth Charles R. | Director / Officer | S-Sale | D | Common Stock | 7,132 | 449.10 | 3.20M | 167,253 | — | ↗ |
| 2021-06-09 | Kelderman Kim | Officer | S-Sale | D | Common Stock | 811 | 433.00 | 351.2K | 0 | — | ↗ |
| 2021-06-07 | Hippel James | Officer | S-Sale | D | Common Stock | 2,396 | 421.93 | 1.01M | 13,147 | — | ↗ |
| 2021-05-25 | Kummeth Charles R. | Director / Officer | M-Exempt | A | Common Stock | 36,849 | 94.35 | 3.48M | 195,690 | — | ↗ |
| 2021-05-25 | Kelderman Kim | Officer | S-Sale | D | Common Stock | 845 | 424.00 | 358.3K | 811 | — | ↗ |
| 2021-05-01 | Kelderman Kim | Officer | M-Exempt | A | Common Stock | 1,667 | 0.00 | — | 2,512 | — | ↗ |
| 2021-03-01 | Furlow Brenda S. | Officer | A-Award | A | Stock Options (Right to Buy) | 10,997 | 372.44 | 4.10M | 10,997 | — | ↗ |
| 2021-02-16 | Kummeth Charles R. | Director / Officer | M-Exempt | A | Common Stock | 30,000 | 94.35 | 2.83M | 176,269 | — | ↗ |
| 2021-02-12 | Hippel James | Officer | S-Sale | D | Common Stock | 9,400 | 400.32 | 3.76M | 9,737 | — | ↗ |
| 2021-02-12 | Furlow Brenda S. | Officer | M-Exempt | A | Common Stock | 10,000 | 106.59 | 1.07M | 16,124 | — | ↗ |
| 2021-02-08 | Nusse Roeland | Director | M-Exempt | A | Common Stock | 5,000 | 66.90 | 334.5K | 12,765 | — | ↗ |
| 2021-02-05 | Kelderman Kim | Officer | S-Sale | D | Common Stock | 823 | 388.45 | 319.7K | 845 | — | ↗ |
| 2021-02-05 | Eansor Norman David | Officer | S-Sale | D | Common Stock | 1,900 | 384.15 | 729.9K | 2,418 | — | ↗ |
| 2021-01-15 | Kummeth Charles R. | Director / Officer | S-Sale | D | Common Stock | 20,000 | 344.00 | 6.88M | 146,269 | — | ↗ |
| 2021-01-11 | Hippel James | Officer | S-Sale | D | Common Stock | 2,501 | 333.23 | 833.4K | 15,136 | — | ↗ |
| 2020-12-07 | Kummeth Charles R. | Director / Officer | S-Sale | D | Common Stock | 5,000 | 308.00 | 1.54M | 166,269 | — | ↗ |
| 2020-11-30 | Furlow Brenda S. | Officer | S-Sale | D | Common Stock | 707 | 302.82 | 214.1K | 6,124 | — | ↗ |
| 2020-11-18 | BAUMGARTNER ROBERT V | Director | M-Exempt | D | Stock Options (right to buy) | 5,000 | 66.90 | 334.5K | 0 | — | ↗ |
| 2020-11-11 | Hippel James | Officer | S-Sale | D | Common Stock | 1,100 | 307.78 | 338.6K | 9,137 | — | ↗ |
| 2020-11-09 | Seth Alpna | Director | M-Exempt | A | Common Stock | 3,125 | 125.05 | 390.8K | 7,162 | — | ↗ |
| 2020-11-09 | Hippel James | Officer | S-Sale | D | Common Stock | 300 | 312.58 | 93.8K | 9,137 | — | ↗ |
| 2020-11-06 | STEER RANDOLPH C | Director | S-Sale | D | Common Stock | 2,535 | 304.59 | 772.1K | 5,112 | — | ↗ |
| 2020-11-06 | Kummeth Charles R. | Director / Officer | M-Exempt | D | Stock Options (Right to Buy) | 25,157 | 86.25 | 2.17M | 0 | — | ↗ |
| 2020-11-06 | HIGGINS JOHN L | Director | M-Exempt | A | Common Stock | 5,000 | 70.35 | 351.8K | 9,412 | — | ↗ |
Executive team
Top executives
EBIT / Employee
34.5K
Shares Outstanding
156.45M
Executive compensation
Executive compensation (annual)
| # | Year | Executive | Salary | Bonus | Stock award | Option award | Incentive | Other | Total | % Stock- based |
Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 2025 | Kim Kelderman President and CEO | 936.0K | — | 3.93M | 1.93M | 1.32M | 33.5K | 8.15M | 71.93% | ↗ |
| 2 | 2025 | James Hippel Executive Vice President and CFO | 723.0K | — | 4.45M | 907.3K | 926.2K | 17.9K | 7.03M | 76.28% | ↗ |
| 3 | 2025 | William Geist President, Protein Sciences | 573.2K | — | 1.21M | 593.4K | 748.0K | 18.0K | 3.14M | 57.34% | ↗ |
| 4 | 2025 | Matthew McManus President, Diagnostics and Spatial Biology | 572.0K | — | 1.21M | 596.7K | 444.8K | 19.9K | 2.85M | 63.58% | ↗ |
| 5 | 2025 | Shane Bohnen Senior Vice President and General Counsel | 431.0K | — | 767.6K | 377.5K | 386.5K | 18.2K | 1.98M | 57.81% | ↗ |
| 6 | 2024 | Kim Kelderman President and CEO | 759.5K | — | 1.94M | 3.86M | 285.4K | 13.7K | 6.85M | 84.55% | ↗ |
| 7 | 2024 | Kim Kelderman President and CEO Former President, Diagnostics and Genomics | 759.5K | — | 1.94M | 3.86M | 285.4K | 13.7K | 6.85M | 84.55% | ↗ |
| 8 | 2024 | Charles R. Kummeth Former President and CEO | 1.18M | — | 5.00M | — | 596.8K | 11.9K | 6.79M | 73.61% | ↗ |
| 9 | 2024 | James Hippel Executive Vice President and CFO | 695.2K | — | 2.11M | 2.17M | 219.0K | 10.6K | 5.20M | 82.23% | ↗ |
| 10 | 2024 | William Geist President, Protein Sciences | 551.2K | — | 1.52M | 1.42M | 144.9K | 13.9K | 3.65M | 80.53% | ↗ |
| 11 | 2024 | Matthew McManus President, Diagnostics and Genomics | 253.8K | — | 1.08M | 527.8K | 124.0K | 7.0K | 1.99M | 80.71% | ↗ |
| 12 | 2024 | Matthew McManus President, Diagnostics and Spatial Biology | 253.8K | — | 1.08M | 527.8K | 124.0K | 7.0K | 1.99M | 80.71% | ↗ |
| 13 | 2024 | Shane Bohnen Senior Vice President and General Counsel | 344.8K | — | 262.5K | 762.5K | 76.0K | 10.0K | 1.46M | 70.41% | ↗ |
| 14 | 2023 | Charles R. Kummeth, President and CEO | 1.18M | — | 5.00M | 24.33M | 54.1K | 21.1K | 30.58M | 95.88% | ↗ |
| 15 | 2023 | Charles R. Kummeth Former President and CEO | 1.18M | — | 5.00M | 24.33M | 54.1K | 21.1K | 30.58M | 95.88% | ↗ |
| 16 | 2023 | James Hippel, Executive Vice President and CFO | 668.4K | — | 687.6K | 2.06M | 13.5K | 9.8K | 3.44M | 79.90% | ↗ |
| 17 | 2023 | James Hippel Executive Vice President and CFO | 668.4K | — | 687.6K | 2.06M | 13.5K | 9.8K | 3.44M | 79.90% | ↗ |
| 18 | 2023 | Kim Kelderman President and CEO | 589.9K | — | 440.1K | 1.32M | 246.7K | 9.1K | 2.61M | 67.54% | ↗ |
| 19 | 2023 | Kim Kelderman President and CEO Former President, Diagnostics and Genomics | 589.9K | — | 440.1K | 1.32M | 246.7K | 9.1K | 2.61M | 67.54% | ↗ |
| 20 | 2023 | Kim Kelderman, President, Diagnostics and Genomics | 589.9K | — | 440.1K | 1.32M | 246.7K | 9.1K | 2.61M | 67.54% | ↗ |
| 21 | 2023 | William Geist President, Protein Sciences | 530.0K | — | 449.9K | 1.35M | — | 3.7K | 2.33M | 77.13% | ↗ |
| 22 | 2023 | Brenda Furlow, Former Executive Vice President and General Counsel | 377.7K | — | 750.1K | 749.9K | 6.3K | 4.6K | 1.89M | 79.43% | ↗ |
| 23 | 2023 | Shane Bohnen, Senior Vice President and General Counsel | 331.5K | — | 499.9K | 190.7K | 22.1K | — | 1.04M | 66.14% | ↗ |
| 24 | 2023 | Shane Bohnen Senior Vice President and General Counsel | 331.5K | — | 499.9K | 190.7K | 22.1K | — | 1.04M | 66.14% | ↗ |
| 25 | 2022 | Charles R. Kummeth, President and CEO | 1.18M | — | 5.15M | 5.15M | 3.86M | 31.5K | 15.37M | 67.01% | ↗ |
| 26 | 2022 | Charles R. Kummeth Former President and CEO | 1.18M | — | 5.15M | 5.15M | 3.86M | 31.5K | 15.37M | 67.01% | ↗ |
| 27 | 2022 | Charles R. Kummeth President and CEO | 1.18M | — | 5.15M | 5.15M | 3.86M | 31.5K | 15.37M | 67.01% | ↗ |
| 28 | 2022 | James Hippel, Executive Vice President and CFO | 636.6K | — | 624.8K | 1.87M | 1.29M | 10.1K | 5.00M | 49.94% | ↗ |
| 29 | 2022 | James Hippel Executive Vice President and CFO | 636.6K | — | 624.8K | 1.87M | 1.29M | 10.1K | 4.44M | 56.35% | ↗ |
| 30 | 2022 | Kim Kelderman, President, Diagnostics and Genomics | 561.8K | — | 399.9K | 1.20M | 776.4K | 9.3K | 3.89M | 41.17% | ↗ |
| 31 | 2022 | David Eansor Former President, Protein Sciences | 448.1K | — | 499.8K | 1.50M | 757.5K | 4.1K | 3.21M | 62.31% | ↗ |
| 32 | 2022 | Brenda Furlow Executive Vice President and General Counsel | 533.7K | — | 374.9K | 1.12M | 915.6K | 9.3K | 2.96M | 50.70% | ↗ |
| 33 | 2022 | Brenda Furlow, Former Executive Vice President and General Counsel | 533.7K | — | 374.9K | 1.12M | 915.6K | 9.3K | 2.96M | 50.70% | ↗ |
| 34 | 2022 | Kim Kelderman President, Diagnostics and Genomics | 561.8K | — | 399.9K | 1.20M | 776.4K | 9.3K | 2.95M | 54.28% | ↗ |
| 35 | 2022 | Kim Kelderman President and CEO Former President, Diagnostics and Genomics | 561.8K | — | 399.9K | 1.20M | 776.4K | 9.3K | 2.95M | 54.28% | ↗ |
| 36 | 2022 | William Geist President, Protein Sciences | 239.6K | — | 1.22M | 674.9K | 425.0K | — | 2.56M | 74.08% | ↗ |
| 37 | 2021 | Charles Kummeth, President and CEO | 1.12M | — | 4.60M | 6.60M | 3.54M | 36.9K | 15.89M | 70.48% | ↗ |
| 38 | 2021 | Charles R. Kummeth, President and CEO | 1.12M | — | 4.60M | 6.60M | 3.54M | 36.9K | 15.89M | 70.48% | ↗ |
| 39 | 2021 | Charles R. Kummeth President and CEO | 1.12M | — | 4.60M | 6.60M | 3.54M | 36.9K | 15.89M | 70.48% | ↗ |
| 40 | 2021 | David Eansor, President, Protein Sciences | 585.0K | — | 459.8K | 4.38M | 1.01M | 8.4K | 6.44M | 75.17% | ↗ |
| 41 | 2021 | David Eansor Former President, Protein Sciences | 585.0K | — | 459.8K | 4.38M | 1.01M | 8.4K | 6.44M | 75.17% | ↗ |
| 42 | 2021 | James Hippel Executive Vice President and CFO | 600.5K | — | 574.8K | 2.72M | 1.10M | 9.4K | 5.00M | 65.93% | ↗ |
| 43 | 2021 | Brenda Furlow, Former Executive Vice President and General Counsel | 503.5K | — | 299.8K | 2.90M | 761.0K | 8.4K | 4.47M | 71.54% | ↗ |
| 44 | 2021 | Brenda Furlow, Executive Vice President and General Counsel | 503.5K | — | 299.8K | 2.90M | 761.0K | 8.4K | 4.47M | 71.54% | ↗ |
| 45 | 2021 | Brenda Furlow Executive Vice President and General Counsel | 503.5K | — | 299.8K | 2.90M | 761.0K | 8.4K | 4.47M | 71.54% | ↗ |
| 46 | 2021 | Kim Kelderman, President, Diagnostics and Genomics) | 530.0K | — | 359.8K | 2.08M | 908.1K | 8.4K | 3.89M | 62.78% | ↗ |
| 47 | 2021 | Kim Kelderman President, Diagnostics and Genomics | 530.0K | — | 359.8K | 2.08M | 908.1K | 8.4K | 3.89M | 62.78% | ↗ |
| 48 | 2021 | James Hippel, Executive Vice President and CFO | 600.5K | — | 574.8K | 2.72M | 1.10M | 9.4K | 3.16M | 104.52% | ↗ |
| 49 | 2021 | Kim Kelderman, President, Diagnostics and Genomics | 530.0K | — | 359.8K | 2.08M | 908.1K | 8.4K | 2.18M | 112.16% | ↗ |
| 50 | 2020 | Charles R. Kummeth President and CEO | 1.05M | — | 4.31M | 4.31M | 1.77M | 41.4K | 11.48M | 75.07% | ↗ |
| 51 | 2020 | Charles Kummeth, President and CEO | 1.05M | — | 4.31M | 4.31M | 1.77M | 41.4K | 11.48M | 75.07% | ↗ |
| 52 | 2020 | James Hippel, Senior Vice President of Finance and CFO | 566.0K | — | 502.4K | 1.50M | 576.7K | 9.5K | 3.16M | 63.49% | ↗ |
| 53 | 2020 | James Hippel Executive Vice President and CFO | 566.0K | — | 502.4K | 1.50M | 576.7K | 9.5K | 3.16M | 63.50% | ↗ |
| 54 | 2020 | James Hippel, Executive Vice President and CFO | 566.0K | — | 502.4K | 1.50M | 576.7K | 9.5K | 3.16M | 63.50% | ↗ |
| 55 | 2020 | David Eansor Former President, Protein Sciences | 552.0K | — | 402.0K | 1.20M | 521.4K | 8.4K | 2.69M | 59.72% | ↗ |
| 56 | 2020 | David Eansor, President, Protein Sciences | 552.0K | — | 402.0K | 1.20M | 521.4K | 8.4K | 2.69M | 59.72% | ↗ |
| 57 | 2020 | Kim Kelderman, President, Diagnostics and Genomics) | 500.0K | — | 301.5K | 901.5K | 464.0K | 8.4K | 2.18M | 55.30% | ↗ |
| 58 | 2020 | Kim Kelderman President, Diagnostics and Genomics | 500.0K | — | 301.5K | 901.5K | 464.0K | 8.4K | 2.18M | 55.30% | ↗ |
| 59 | 2020 | Kim Kelderman, President, Diagnostics and Genomics | 500.0K | — | 301.5K | 901.5K | 464.0K | 8.4K | 2.18M | 55.30% | ↗ |
| 60 | 2020 | Brenda Furlow Executive Vice President and General Counsel | 475.0K | — | 251.2K | 751.2K | 337.8K | 8.4K | 1.82M | 54.97% | ↗ |
| 61 | 2020 | Brenda Furlow, Executive Vice President and General Counsel | 475.0K | — | 251.2K | 751.2K | 337.8K | 8.4K | 1.82M | 54.97% | ↗ |
| 62 | 2020 | Brenda Furlow, Senior Vice President – General Counsel | 475.0K | — | 251.2K | 751.2K | 337.8K | 8.4K | 1.82M | 54.97% | ↗ |
| 63 | 2019 | Charles Kummeth, President and CEO | 957.0K | — | 4.00M | 4.00M | 2.01M | 45.7K | 11.01M | 72.66% | ↗ |
| 64 | 2019 | James Hippel, Senior Vice President of Finance and CFO | 514.2K | — | 399.9K | 1.20M | 634.3K | 9.3K | 2.76M | 58.02% | ↗ |
| 65 | 2019 | James Hippel, Executive Vice President and CFO | 514.2K | — | 399.9K | 1.20M | 634.3K | 9.3K | 2.76M | 58.02% | ↗ |
| 66 | 2019 | David Eansor, Senior Vice President- Biotechnology | 501.4K | — | 299.9K | 900.1K | 613.4K | 8.3K | 2.32M | 51.65% | ↗ |
| 67 | 2019 | David Eansor, President, Protein Sciences | 501.4K | — | 299.9K | 900.1K | 613.4K | 8.3K | 2.32M | 51.65% | ↗ |
| 68 | 2019 | Kim Kelderman, President, Diagnostics and Genomics | 452.4K | — | 199.9K | 600.0K | 304.8K | 8.3K | 1.57M | 51.10% | ↗ |
| 69 | 2019 | Kim Kelderman, President, Diagnostics and Genomics) | 452.4K | — | 199.9K | 600.0K | 304.8K | 8.3K | 1.57M | 51.10% | ↗ |
| 70 | 2019 | Brenda Furlow, Senior Vice President – General Counsel | 431.4K | — | 162.4K | 487.5K | 350.6K | 8.3K | 1.48M | 43.80% | ↗ |
| 71 | 2019 | Brenda Furlow, Executive Vice President and General Counsel | 431.4K | — | 162.4K | 487.5K | 350.6K | 8.3K | 1.44M | 45.13% | ↗ |
| 72 | 2018 | Charles Kummeth, President and CEO | 911.0K | — | 3.55M | 3.55M | 1.61M | 42.9K | 9.66M | 73.46% | ↗ |
| 73 | 2018 | James Hippel, Senior Vice President of Finance and CFO | 476.1K | — | 370.0K | 1.11M | 483.5K | 9.3K | 2.45M | 60.44% | ↗ |
| 74 | 2018 | David Eansor, Senior Vice President-Biotechnology | 455.0K | — | 2.00 | 3.00 | 403.2K | 5.00 | 1.59M | 0.00% | ↗ |
| 75 | 2018 | David Eansor, President, Protein Sciences | 455.0K | — | 181.2K | 543.8K | 403.2K | 8.1K | 1.59M | 45.56% | ↗ |
| 76 | 2018 | David Eansor, Senior Vice President- Biotechnology | 455.0K | — | 181.2K | 543.8K | 403.2K | 8.1K | 1.59M | 45.56% | ↗ |
| 77 | 2018 | Robert Gavin, Senior Vice President-Protein Platforms | 393.8K | — | 6.00 | 7.00 | 322.7K | 9.00 | 1.37M | 0.00% | ↗ |
| 78 | 2018 | Brenda Furlow, Senior Vice President – General Counsel | 385.0K | — | 143.7K | 431.2K | 250.1K | 8.1K | 1.22M | 47.20% | ↗ |
| 79 | 2018 | Kim Kelderman, President, Diagnostics and Genomics | 72.5K | — | 753.9K | 301.6K | 36.3K | 1.0K | 1.17M | 90.58% | ↗ |
| 80 | 2017 | Charles Kummeth, President and CEO | 880.0K | — | 3.55M | 3.55M | 1.05M | 43.8K | 9.08M | 78.22% | ↗ |
| 81 | 2017 | Charles R. Kummeth, President and CEO | 880.0K | — | 3.55M | 3.55M | 1.05M | 43.8K | 9.08M | 78.22% | ↗ |
| 82 | 2017 | James Hippel, Senior Vice President of Finance and CFO | 460.0K | — | 350.0K | 1.05M | 356.3K | 10.7K | 2.23M | 62.86% | ↗ |
| 83 | 2017 | David Eansor, Senior Vice President-Biotechnology | 430.0K | — | 2.00 | 3.00 | 256.2K | 11.1K | 1.35M | 0.00% | ↗ |
| 84 | 2017 | David Eansor, Senior Vice President- Biotechnology | 430.0K | — | 162.5K | 487.4K | 256.2K | 11.1K | 1.35M | 48.24% | ↗ |
| 85 | 2017 | Robert Gavin, Senior Vice President-Protein Platforms | 375.0K | — | 6.00 | 7.00 | 226.4K | 13.9K | 1.22M | 0.00% | ↗ |
| 86 | 2017 | Kevin Gould, Senior Vice President - Diagnostics | 365.0K | — | 150.0K | 449.9K | 129.3K | 7.9K | 1.10M | 54.43% | ↗ |
| 87 | 2017 | Brenda Furlow, Senior Vice President – General Counsel | 350.0K | — | 125.0K | 374.9K | 166.8K | 8.0K | 1.02M | 48.79% | ↗ |
| 88 | 2016 | Charles Kummeth, President and CEO | 800.0K | — | 2.50M | 2.91M | 1.22M | 38.2K | 7.47M | 72.42% | ↗ |
| 89 | 2016 | Charles R. Kummeth, President and CEO | 800.0K | — | 2.50M | 2.91M | 1.22M | 38.2K | 7.47M | 72.42% | ↗ |
| 90 | 2016 | James Hippel, Senior Vice President of Finance and CFO | 425.0K | — | 8.00 | 9.00 | 421.7K | 9.0K | 1.76M | 0.00% | ↗ |
| 91 | 2016 | Kevin Gould, Senior Vice President - Clinical Controls | 275.0K | — | 243.1K | 969.0K | 145.5K | 4.8K | 1.49M | 81.22% | ↗ |
| 92 | 2016 | Kevin Gould, Senior Vice President - Diagnostics | 275.0K | — | 243.1K | 969.0K | 145.5K | 4.8K | 1.49M | 81.22% | ↗ |
| 93 | 2016 | David Eansor, Senior Vice President- Biotechnology | 400.0K | — | 108.5K | 342.9K | 282.1K | 8.0K | 1.14M | 39.55% | ↗ |
| 94 | 2016 | David Eansor, Senior Vice President-Biotechnology | 400.0K | — | 2.00 | 3.00 | 282.1K | 8.0K | 1.14M | 0.00% | ↗ |
| 95 | 2016 | Robert Gavin, Senior Vice President- Protein Platforms | 350.0K | — | 108.5K | 342.9K | 136.3K | 5.3K | 943.0K | 47.87% | ↗ |
| 96 | 2016 | Robert Gavin, Senior Vice President-Protein Platforms | 350.0K | — | 6.00 | 7.00 | 136.3K | 5.3K | 943.0K | 0.00% | ↗ |
| 97 | 2016 | Brenda Furlow, Senior Vice President – General Counsel | 300.0K | — | 20.00 | 21.00 | 137.4K | 8.0K | 806.5K | 0.01% | ↗ |
| 98 | 2015 | Charles R. Kummeth, President and CEO | 625.0K | — | 700.0K | 700.0K | 671.2K | 40.5K | 2.74M | 51.16% | ↗ |
| 99 | 2015 | Robert Gavin, Senior Vice President Protein Platforms | 276.3K | — | 466.6K | 1.01M | 124.0K | — | 1.90M | 77.83% | ↗ |
| 100 | 2015 | David Eansor, Senior Vice President- Biotechnology | 325.0K | — | 468.3K | 195.8K | 85.6K | 18.0K | 1.09M | 60.77% | ↗ |
| 101 | 2015 | David Eansor, Senior Vice President Biotechnology | 324.1K | — | 468.3K | 195.8K | 85.6K | 18.0K | 1.09M | 60.82% | ↗ |
| 102 | 2015 | James Hippel, Chief Financ ial Officer | 350.0K | — | — | 456.8K | 244.3K | 7.8K | 1.06M | 43.14% | ↗ |
| 103 | 2015 | James Hippel, Senior Vice President of Finance and CFO | 350.0K | — | — | 456.8K | 244.3K | 7.8K | 1.06M | 43.14% | ↗ |
| 104 | 2015 | Brenda Furlow, Senior Vice President and General Counsel | 221.2K | — | 232.9K | 195.8K | 67.1K | 37.1K | 754.0K | 56.85% | ↗ |
| 105 | 2015 | Robert Gavin, Senior Vice President- Protein Platforms | 325.0K | — | — | 228.1K | 124.0K | — | 677.1K | 33.68% | ↗ |
| 106 | 2015 | Robert Gavin, Senior Vice President-Protein Platforms | 325.0K | — | — | 228.1K | 124.0K | — | 677.1K | 33.68% | ↗ |
| 107 | 2014 | Charles R. Kummeth, President and CEO | 586.4K | — | 1.54M | 600.0K | 421.0K | 33.1K | 3.18M | 67.28% | ↗ |
| 108 | 2014 | Charles R. Kummeth, President and CEO | 586.4K | — | 1.54M | 600.0K | 421.0K | 33.1K | 3.18M | 67.28% | ↗ |
| 109 | 2014 | James Hippel, Vice President of Finance and CFO | 79.4K | — | 431.3K | 498.8K | 20.0K | 133.6K | 1.16M | 79.96% | ↗ |
| 110 | 2014 | James Hippel, Chief Financ ial Officer | 79.4K | 20.0K | 431.3K | 498.8K | — | 133.6K | 1.16M | 79.96% | ↗ |
| 111 | 2014 | James Hippel, Senior Vice President of Finance and CFO | 79.4K | 20.0K | 431.3K | 498.8K | — | 133.6K | 1.16M | 79.96% | ↗ |
| 112 | 2014 | Fernando Bazan, Chief Technology Officer | 223.1K | — | — | 336.3K | 55.9K | 3.8K | 619.0K | 54.32% | ↗ |
| 113 | 2014 | Kevin Reagan, Senior Vice President Biotechnology | 276.5K | — | — | 201.8K | 52.1K | 4.1K | 534.5K | 37.75% | ↗ |
| 114 | 2014 | Marcel Veronneau, Senior Vice President—Clinical Controls | 225.0K | — | — | 201.8K | 37.4K | 3.4K | 467.6K | 43.15% | ↗ |
| 115 | 2014 | Gregory J. Melsen, Former Vice-President —Finance, Treasurer and CFO | 271.2K | — | — | 269.0K | 109.4K | — | 380.6K | 70.68% | ↗ |
| 116 | 2014 | Brenda Furlow, Senior Vice President and General Counsel | — | — | — | — | — | — | — | — | ↗ |
| 117 | 2014 | David Eansor, Senior Vice President Biotechnology | — | — | — | — | — | — | — | — | ↗ |
| 118 | 2014 | Robert Gavin, Senior Vice President Protein Platforms | — | — | — | — | — | — | — | — | ↗ |
| 119 | 2013 | Charles R. Kummeth, President and CEO | 143.8K | — | 1.01M | 964.9K | 107.8K | 13.2K | 2.24M | 88.19% | ↗ |
| 120 | 2013 | Charles R. Kummeth, President and CEO | 143.8K | — | 1.01M | — | 107.8K | 13.2K | 2.24M | 45.14% | ↗ |
| 121 | 2013 | Gregory J. Melsen, Vice President – Finance,Treasurer | 384.4K | — | — | 154.4K | 225.0K | — | 763.4K | 20.22% | ↗ |
| 122 | 2013 | Gregory J. Melsen, Former Vice-President —Finance, Treasurer and CFO | 384.4K | — | — | 174.3K | 225.0K | — | 763.4K | 22.84% | ↗ |
| 123 | 2013 | Marcel Veronneau, Senior Vice President – Clinical Controls (formerly Hematology) | 210.0K | — | — | — | — | — | 210.0K | 0.00% | ↗ |
| 124 | 2013 | Marcel Veronneau, Senior Vice President—Clinical Controls | 210.0K | — | — | 12.5K | — | — | 210.0K | 5.95% | ↗ |
| 125 | 2013 | Thomas E. Oland, Former President and CEO | 112.4K | — | — | — | — | 28.0K | 140.4K | 0.00% | ↗ |
| 126 | 2013 | James Hippel, Chief Financ ial Officer | — | — | — | — | — | — | — | — | ↗ |
| 127 | 2013 | James Hippel, Vice President of Finance and CFO | — | — | — | — | — | — | — | — | ↗ |
| 128 | 2013 | Brenda Furlow, Senior Vice President and General Counsel | — | — | — | — | — | — | — | — | ↗ |
| 129 | 2013 | Robert Gavin, Senior Vice President Protein Platforms | — | — | — | — | — | — | — | — | ↗ |
| 130 | 2013 | David Eansor, Senior Vice President Biotechnology | — | — | — | — | — | — | — | — | ↗ |
| 131 | 2013 | Fernando Bazan, Chief Technology Officer | — | — | — | — | — | — | — | — | ↗ |
| 132 | 2013 | Kevin Reagan, Senior Vice President Biotechnology | — | — | — | — | — | — | — | — | ↗ |
| 133 | 2012 | Marcel Veronneau, Vice President - Hematology Operations | 200.0K | — | — | 285.5K | 12.5K | 6.6K | 504.6K | 56.58% | ↗ |
| 134 | 2012 | Marcel Veronneau, Senior Vice President—Clinical Controls | 200.0K | — | — | 288.4K | 12.5K | 6.6K | 504.6K | 57.16% | ↗ |
| 135 | 2012 | Marcel Veronneau, Senior Vice President – Clinical Controls (formerly Hematology) | 200.0K | — | — | 285.5K | 12.5K | 6.6K | 504.6K | 56.58% | ↗ |
| 136 | 2012 | Gregory J. Melsen, Vice President – Finance, Treasurer and CFO | 315.0K | — | — | 20.0K | 20.0K | 7.2K | 362.2K | 5.52% | ↗ |
| 137 | 2012 | Gregory J. Melsen, Vice President – Finance,Treasurer | 315.0K | — | — | 20.0K | 20.0K | 7.2K | 362.2K | 5.52% | ↗ |
| 138 | 2012 | Gregory J. Melsen, Former Vice-President —Finance, Treasurer and CFO | 315.0K | — | — | 24.6K | 20.0K | 7.2K | 362.2K | 6.79% | ↗ |
| 139 | 2012 | Thomas E. Oland, President and CEO | 254.1K | — | — | — | — | 7.2K | 261.3K | 0.00% | ↗ |
| 140 | 2012 | Thomas E. Oland, Former President and CEO | 254.1K | — | — | — | — | 7.2K | 261.3K | 0.00% | ↗ |
| 141 | 2012 | James Hippel, Vice President of Finance and CFO | — | — | — | — | — | — | — | — | ↗ |
| 142 | 2012 | Fernando Bazan, Chief Technology Officer | — | — | — | — | — | — | — | — | ↗ |
| 143 | 2012 | Kevin Reagan, Senior Vice President Biotechnology | — | — | — | — | — | — | — | — | ↗ |
| 144 | 2012 | Charles R. Kummeth, President and CEO | — | — | — | — | — | — | — | — | ↗ |
| 145 | 2012 | Charles R. Kummeth, President and CEO | — | — | — | — | — | — | — | — | ↗ |
| 146 | 2011 | Gregory J. Melsen, Vice President – Finance, Treasurer and CFO | 290.0K | — | — | 24.6K | 24.6K | 12.3K | 351.6K | 7.00% | ↗ |
| 147 | 2011 | Gregory J. Melsen, Vice President – Finance,Treasurer | 290.0K | — | — | 24.6K | 24.6K | 12.3K | 351.6K | 7.00% | ↗ |
| 148 | 2011 | Thomas E. Oland, President and CEO | 254.1K | — | — | — | — | 12.3K | 266.4K | 0.00% | ↗ |
| 149 | 2011 | Thomas E. Oland, Former President and CEO | 254.1K | — | — | — | — | 12.3K | 266.4K | 0.00% | ↗ |
| 150 | 2011 | Marcel Veronneau, Senior Vice President – Clinical Controls (formerly Hematology) | 185.0K | — | — | 15.4K | 15.4K | 9.9K | 225.7K | 6.83% | ↗ |
| 151 | 2011 | Marcel Veronneau, Vice President - Hematology Operations | 185.0K | — | — | 15.4K | 15.4K | 9.9K | 225.7K | 6.83% | ↗ |
| 152 | 2011 | Charles R. Kummeth, President and CEO | — | — | — | — | — | — | — | — | ↗ |
| 153 | 2010 | Gregory J. Melsen, Vice President – Finance, Treasurer and CFO | 275.0K | — | — | 350.1K | 19.5K | 4.2K | 648.7K | 53.97% | ↗ |
| 154 | 2010 | Marcel Veronneau, Vice President - Hematology Operations | 167.5K | — | — | 122.2K | 12.0K | 3.4K | 305.0K | 40.06% | ↗ |
| 155 | 2010 | Thomas E. Oland, President and CEO | 254.1K | — | — | — | — | 4.2K | 258.3K | 0.00% | ↗ |
| 156 | 2009 | Gregory J. Melsen, Vice President – Finance, Treasurer and CFO | 275.0K | — | — | 2.2K | 12.7K | 7.8K | 297.6K | 0.72% | ↗ |
| 157 | 2009 | Thomas E. Oland, President and CEO | 254.1K | — | — | — | — | 7.8K | 261.9K | 0.00% | ↗ |
| 158 | 2009 | Marcel Veronneau, Vice President - Hematology Operations | 167.5K | — | — | 5.2K | 30.9K | 7.0K | 210.6K | 2.48% | ↗ |
CEO compensation breakdown
Proxy statements
Proxy statements (DEF 14A)
Recent SEC filings
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Kim Kelderman | Chief Executive Officer, President & Director | 2M | male |
| James T. Hippel | Executive Vice President of Finance & Chief Financial Officer | 2M | male |
| William A. Geist | President of Protein Sciences Segment | 1M | male |
| Shane Bohnen | Senior Vice President, General Counsel, Corporate Secretary & Chief Sustainability Officer | 835.7K | male |
| Gary J. Latham | Vice President & Chief Technology Officer | — | — |
| David Clair | Vice President of Investor Relations & Corporate Development | — | male |
| Gerry Andros | Vice President of Sales and Marketing | — | male |
| Martin Wirtz | Senior Vice President of Strategy & Corporate Development | — | male |
| Cheryl Bethune | Senior Vice President & Chief Human Resources Officer | — | female |
| Luca Cicchetti | Managing Director | — | male |
ESG Rating
ESG Score History BIOTECHNOLOGY
Benchmark vs Sector
Political Trading Activity (25M)
Senate Trading Activity
| Transaction Date | Disclosed | Senator | State | Owner | Type | Amount | Link |
|---|---|---|---|---|---|---|---|
| 2015-02-13 | 2015-02-26 | Thom Tillis | NC | Joint | Sale (Full) | $1,001 - $15,000 | ↗ |
House Trading Activity
| Transaction Date | Disclosed | Representative | District | Owner | Type | Amount | Link |
|---|---|---|---|---|---|---|---|
| 2026-03-26 | 2026-04-08 | April Delaney | MD06 | — | Sale | $1,001 - $15,000 | ↗ |
| 2026-02-24 | 2026-03-11 | April Delaney | MD06 | — | Sale | $1,001 - $15,000 | ↗ |
| 2026-01-28 | 2026-02-03 | April Delaney | MD06 | — | Sale | $1,001 - $15,000 | ↗ |
| 2025-12-05 | 2026-01-06 | April Delaney | MD06 | — | Purchase | $1,001 - $15,000 | ↗ |
| 2025-12-02 | 2026-01-06 | April Delaney | MD06 | — | Purchase | $1,001 - $15,000 | ↗ |
| 2025-10-22 | 2025-11-05 | April Delaney | MD06 | — | Purchase | $1,001 - $15,000 | ↗ |
| 2025-08-01 | 2025-09-03 | April Delaney | MD06 | — | Sale | $1,001 - $15,000 | ↗ |
| 2025-05-26 | 2025-07-03 | April Delaney | MD06 | — | Sale | $1,001 - $15,000 | ↗ |
| 2025-04-29 | 2025-05-02 | April Delaney | MD06 | Dependent | Purchase | $1,001 - $15,000 | ↗ |
| 2025-04-09 | 2025-05-02 | April Delaney | MD06 | Dependent | Purchase | $1,001 - $15,000 | ↗ |
| 2025-04-08 | 2025-05-08 | Rob Bresnahan | PA08 | — | Sale (Full) | $1,001 - $15,000 | ↗ |
| 2025-04-01 | 2025-05-15 | Julie Johnson | TX32 | Joint | Sale | $1,001 - $15,000 | ↗ |
| 2025-02-25 | 2025-03-28 | Rob Bresnahan | PA08 | — | Purchase | $1,001 - $15,000 | ↗ |
| 2023-11-03 | 2023-12-06 | Ro Khanna | CA17 | — | Sale | $1,001 - $15,000 | ↗ |
| 2023-10-02 | 2023-11-08 | Ro Khanna | CA17 | — | Purchase | $1,001 - $15,000 | ↗ |
| 2023-06-26 | 2023-07-11 | Ro Khanna | CA17 | — | Sale | $1,001 - $15,000 | ↗ |
| 2023-05-23 | 2023-06-12 | Ro Khanna | CA17 | — | Purchase | $1,001 - $15,000 | ↗ |
| 2023-04-10 | 2023-05-08 | Ro Khanna | CA17 | Spouse | Sale | $1,001 - $15,000 | ↗ |
| 2023-03-14 | 2023-04-07 | Ro Khanna | CA17 | Spouse | Purchase | $1,001 - $15,000 | ↗ |
| 2023-02-10 | 2023-03-08 | Ro Khanna | CA17 | Spouse | Sale | $1,001 - $15,000 | ↗ |
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for TECH
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
